3-substituted sulfonyl piperidine derivative

ABSTRACT

[Problem] There is provided a compound useful as a preventive or remedy for cardiovascular disease, neurologic disease, metabolic disease, reproductive disease, and digestive disease. 
     [Means for Resolution] A compound or a pharmaceutically acceptable salt thereof represented by the following Formula (I) 
     
       
         
         
             
             
         
       
     
     wherein Z represents 
     
       
         
         
             
             
         
       
     
     wherein n1, n2, and n3 are 0, 1, or 2, respectively; R 1  represents C 1-6  alkyl, C 3-8  cycloalkyl, or the like; R 2  represents aryl or heteroaryl; R 3  represents a hydrogen atom, C 1-6  alkyl, or the like; and M 1 , M 2 , M 3 , and M 4  independently represent a hydrogen atom, C 1-6  alkyl, or the like, or M 1 , together with M 2 , M 3 , or M 4 , forms —CH 2 — or the like.

TECHNICAL FIELD

The present invention is useful in the field of medicine. Specifically,a 3-substituted sulfonylpiperidine derivative of the present inventionserves as an inhibitor of long chain fatty acyl elongase (hereinafter,also referred to as “LCE”), and is useful as a remedy for a variety ofdiseases such as cardiovascular disease, neurologic disease, metabolicdisease, reproductive disease, digestive disease, neoplasm, andinfection. The invention is also useful as a herbicide.

BACKGROUND ART

Obesity is a condition characterized by accumulation of neutral fat inthe fat cell after a sustained state of excessive caloric intake overconsumed calories, manifested as a notably higher body weight than thestandard body weight (Eiji Itagaki, STEP Taisha.Naibunpi, KaibashoboInc., 1st Ed., 1998, p. 105). The excess fat accumulation causesdiseases, for example, such as insulin resistance, diabetes mellitus,hypertension, and hyperlipidemia. Combined, these factors are known tosignificantly increase the risk of atherosclerosis onset, and the term“metabolic syndrome” has been used to describe cases associated withsuch risk factors.

Further, neutral fat hyperlipaemia or obesity is known to increase therisk of onset of diseases, for example, such as pancreatitis, liverdysfunction, cancers (including breast cancer, uterine cancer, ovariancancer, colon cancer, and prostate cancer), emmeniopathy, arthritis,gout, cholecystitis, gastroesophageal reflux, obesity-hypoventilationsyndrome (Pickwickian syndrome), and sleep apnea. It is widely knownthat diabetes often leads to, onset of, for example, such as angina,heart failure, stroke, claudication, retinopathy, failing vision, kidneyfailure, neuropathy, skin ulcer, and infection [The Merck Manual ofMedical Information, 2nd Home Edition, Merck & Co., 2003].

LCE, present in the endoplasmic reticulum of the cell, is a member ofenzymes that catalyze the carbon chain elongation reaction of fattyacids having carbon chains of 12 or more carbon atoms, catalyzing therate-limiting condensation step. In mammals, many of the fatty acidsthat are synthesized de novo in the body possess chain lengths of 16 to18 carbon atoms. These long chain fatty acids constitute more than 90%of all fatty acids present in cells. They are important components ofcell membranes, and represent the major components of fat tissues, thelargest energy storage reservoir in animals. The highest rate of de novofatty acid synthesis occurs in liver, converting excess glucose in thebody into fatty acids. Glycolysis converts glucose into pyruvate, whichis converted to citrate in the mitochondria and transported to thecytosol. Cytosolic ATP citrate lyase generates acetyl-CoA, the precursorof fatty acids and cholesterol. Acetyl-CoA is carboxylated by acetyl-CoAcarboxylase (ACC) to form malonyl-CoA. The multifunction enzyme fattyacid synthase (FAS) uses malonyl-CoA, acetyl-CoA, and NADPH to elongatefatty acids in 2-carbon increments. The principal end product of FAS inrodents is palmitoyl-CoA, which has a carbon chain of 16 carbon atoms.LCE elongates the carbon chain of palmitoyl-CoA in 2-carbon increments[The Journal of Biological Chemistry, 276(48), 45358-45366, (2001)]. Itis known that an excess fatty acid synthesis in the body increasesneutral or other fats, causing fat accumulation. For example, a directassociation between LCE and obesity is indicated in WO2005/005665(Patent Document 1). There is also a report that feeding varies theexpression level of mouse FACE (LCE) (Matsuzaka T. et al., J. LipidRes., 43(6):911-920 (2002); Non-Patent Document 1).

LCE is also present in protozoa and nematodes, and its involvement inthe proliferation of cells is known. For example, there has been areport that Trypanosoma, a protozoon that causes African trypanosomiasis(more commonly, African sleeping sickness), uses a fatty acid elongationpathway with LCE to synthesize long chain fatty acids, and that theinhibition of the fatty acid elongation reaction in the cell affects thegrowth of Trypanosoma (Lee S. H. et al., Cell, 126:691-699 (2006);Non-Patent Document 2).

There has been no compound known to possess an LCE inhibiting effect.The 3-substituted sulfonylpiperidine derivative, a compound of thepresent invention, has phenyl or heteroaryl at position 3 via an amidebond. To date, no compound has been known that has a specificsubstituent, such as arylamide or heteroarylamide, at position 3, orthat forms an azabicyclo ring instead of a piperidine ring, and has aspecific substituent, such as arylamide or heteroarylamide, at position3.

Patent Document 1: A Pamphlet of International Publication 2005/005665

Non-Patent Document 1: J. Lipid Res., 43(6), 911-920 (2002)

Non-Patent Document 2: Cell, 126:691-699 (2006)

DISCLOSURE OF THE INVENTION Problems that the Invention is to Solve

An object of the present invention is to provide a novel compound havingan LCE inhibiting effect.

Means for Solving the Problems

The inventors of the present invention conducted intensive studies, andfound that a sulfonylpiperidine derivative having a specific substituentat position 3 of the piperidine skeleton has an excellent LCE inhibitingeffect. The present invention was completed based on this finding.

Specifically, the present invention provides;

(1) a compound represented by the following Formula (I) or apharmaceutically acceptable salt thereof (hereinafter, “compound of thepresent invention”);

wherein,

Z is selected from the group consisting of the following Formulae(II-1), (II-2), and (II-3)

where n1, n2, and n3 are 0, 1, or 2, respectively wherein,

R¹ represents C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or heteroaryl, whereinthe alkyl, cycloalkyl, aryl, or heteroaryl may be substituted with asubstituent selected from the group consisting of: hydroxy, cyano,carboxyl, sulfo, halogen, C₁₋₆ alkyl, halo C₁₋₆ alkyl, C₃₋₈ cycloalkyl,C₁₋₆ alkoxy, halo C₁₋₆ alkoxy, amino (the amino being optionallysubstituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls), carbamoyl(the carbamoyl being optionally substituted with 1 to 2 C₁₋₆ alkyls,aryls, or heteroaryls), sulfanyl (the sulfanyl being optionallysubstituted with one C₁₋₆ alkyl, aryl, or heteroaryl), C₁₋₆alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, C₁₋₆ alkylsulfonyl,arylsulfonyl, heteroarylsulfonyl, sulfamoyl (the sulfamoyl beingoptionally substituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls),C₁₋₆ alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,C₁₋₆ alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C₁₋₆alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, carbamoylamino(the carbamoylamino being optionally substituted with 1 to 2 C₁₋₆alkyls, aryls, or heteroaryls), C₁₋₆ alkoxycarbonylamino,aryloxycarbonylamino, heteroaryloxycarbonylamino, C₁₋₆alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aryl,heteroaryl, aralkyl, heteroaralkyl, aralkyloxy, and heteroaralkyloxy;

R² represents phenyl or heteroaryl, wherein the phenyl or heteroaryl maybe substituted with a substituent selected from the group consisting of:hydroxy, cyano, carboxyl, sulfo, halogen, C₁₋₆ alkyl, halo C₁₋₆ alkyl,C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, halo C₁₋₆ alkoxy, amino (the amino beingoptionally substituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls),carbamoyl (the carbamoyl being optionally substituted with 1 to 2 C₁₋₆alkyls, aryls, or heteroaryls), sulfanyl (the sulfanyl being optionallysubstituted with one C₁₋₆ alkyl, aryl, or heteroaryl), C₁₋₆alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, C₁₋₆ alkylsulfonyl,arylsulfonyl, heteroarylsulfonyl, sulfamoyl (the sulfamoyl beingoptionally substituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls),C₁₋₆ alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,C₁₋₆ alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C₁₋₆alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, carbamoylamino(the carbamoylamino being optionally substituted with 1 to 2 C₁₋₆alkyls, aryls, or heteroaryls), C₁₋₆ alkoxycarbonylamino,aryloxycarbonylamino, heteroaryloxycarbonylamino, C₁₋₆alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aryl(the aryl being optionally substituted with C₁₋₆ alkoxy), heteroaryl,aryloxy, heteroaryloxy, aralkyl, heteroaralkyl, aralkyloxy, andheteroaralkyloxy;

R³ represents a hydrogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aralkyl,heteroaralkyl, aryl, or heteroaryl, wherein the alkyl, cycloalkyl,aralkyl, heteroaralkyl, aryl, or heteroaryl may be substituted with asubstituent selected from the group consisting of halogen, C₁₋₆ alkyl,halo C₁₋₆ alkyl, C₁₋₆ alkoxy, and halo C₁₋₆ alkoxy; and

M₁, M₂, M₃, and M₄ represent each independently a hydrogen atom or C₁₋₆alkyl which may be substituted with halogen; or M₁, together with M₂, M₃or M₄, forms —CH₂— or —CH₂—CH₂—, or M₄, together with M₂, forms —CH₂— or—CH₂—CH₂—, provided that any two of M₁, M₂, M₃ and M₄ together form—CH₂— or —CH₂—CH₂— when R³ is a hydrogen atom.

The present invention further provides:

(2) A long chain fatty acyl elongase (LCE) inhibitor, which contains thecompound of Formula (I) or the pharmaceutically acceptable salt thereofas an active ingredient;

(3) A pharmaceutical composition, which contains the compound of Formula(I) or the pharmaceutically acceptable salt thereof; and

(4) A preventive or remedy for diabetes mellitus, obesity, ornon-alcoholic fatty liver, which contains the compound of Formula (I) orthe pharmaceutically acceptable salt thereof as an active ingredient.

A compound of the present invention has an LCE inhibiting effect, and istherefore useful as a preventive or remedy for a variety of diseasesinvolving LCE, for example, such as cardiovascular disease, including,for example, hypertension, angina, heart failure, myocardial infarction,stroke, claudication, diabetic nephropathy, diabetic retinopathy,failing vision, electrolyte abnormalities, and atherosclerosis; centralneurologic disease, including, for example, bulimia and diabeticneuropathy; metabolic disease, including, for example, metabolicsyndrome, obesity, diabetes mellitus, insulin resistance,hyperlipidemia, hypercholesteremia, neutral fat hyperlipaemia,dyslipidemia, non-alcoholic fatty liver, abnormal hormone secretion,gout, and fatty liver; reproductive disease, including, for example,menstrual disturbance and sexual dysfunction; digestive disease,including liver dysfunction, pancreatitis, cholecystitis, andgastroesophageal reflux; respiratory disease, includingobesity-hypoventilation syndrome (Pickwickian syndrome), and sleepapnea; bacterial, fungal, or parasitic infectious disease; malignantneoplasm; and inflammatory disease, including arthritis, and skin ulcer.A compound of the present invention is also useful as a herbicide.

A compound of the present invention is particularly useful as a remedyfor, for example, diabetes mellitus, obesity, or non-alcoholic fattyliver, or as a herbicide.

The present invention is described below in more detail, beginning withthe definitions of the terms used herein.

The “halogen” means a fluorine atom, a chlorine atom, a bromine atom, oran iodine atom.

The “C₁₋₆ alkyl” means straight-chain or branched alkyl having 1 to 6carbon atoms, for example, such as methyl, ethyl, propyl, isopropyl,butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, andisohexyl.

The “halo C₁₋₆ alkyl” means the C₁₋₆ alkyl as defined above, substitutedwith one or more, preferably 1 to 3 halogen atoms at arbitrary availablesubstitution positions, the halogen atoms being the same or differentand as defined above. Examples include fluoromethyl, difluoromethyl,trifluoromethyl, 2-fluoroethyl, 1,2-difluoroethyl, chloromethyl,2-chloroethyl, 1,2-dichloroethyl, bromomethyl, and iodomethyl.

The “C₃₋₈ cycloalkyl” means cycloalkyl having 3 to 8 carbon atoms, forexample, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The “C₁₋₆ alkoxy” means straight-chain or branched alkoxy having 1 to 6carbon atoms, for example, such as methoxy, ethoxy, propoxy, isopropoxy,butoxy, sec-butoxy, isobutoxy, tert-butoxy, pentyloxy, isopentyloxy,hexyloxy, and isohexyloxy.

The “halo C₁₋₆ alkoxy” means the C₁₋₆ alkoxy as defined above,substituted with one or more, preferably 1 to 3 halogen atoms atarbitrary available substitution positions, the halogen atoms being thesame or different and as defined above. Examples include fluoromethoxy,difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 1,2-difluoroethoxy,chloromethoxy, 2-chloroethoxy, 1,2-dichloroethoxy, bromomethoxy, andiodomethoxy.

The “C₁₋₆ alkoxycarbonyl” is a group with the C₁₋₆ alkoxy bound tocarbonyl. Examples include methoxycarbonyl, ethoxycarbonyl, andn-propyloxycarbonyl.

The “C₁₋₆ alkoxycarbonylamino” is a group in which one of the hydrogenatoms of the amino group(—NH₂) is substituted with the C₁₋₆alkoxycarbonyl. Examples include methoxycarbonylamino,ethoxycarbonylamino, and n-propyloxycarbonylamino

The “C₁₋₆ alkylcarbonyl” is a group with the C₁₋₆ alkyl bound tocarbonyl. Examples include acetyl, propionyl, isobutyryl, valeryl,isovaleryl, and pivaloyl.

The “C₁₋₆ alkylcarbonylamino” is a group in which one of the hydrogenatoms of the amino group is substituted with the C₁₋₆ alkylcarbonyl.Examples include acetylamino, propionylamino, isobutyrylamino,valerylamino, isovalerylamino, and pivaloylamino

The “C₁₋₆ alkylsulfonyl” means a group with the C₁₋₆ alkyl bound to asulfonyl group. Examples include methylsulfonyl, ethylsulfonyl, andn-propylsulfonyl.

The “C₁₋₆ alkylsulfonylamino” is a group in which one of the hydrogenatoms of the amino group is substituted with the C₁₋₆ alkylsulfonyl.Examples include methylsulfonylamino, ethylsulfonylamino, andn-propylsulfonylamino

The “C₁₋₆ alkylsulfinyl” is a group with the C₁₋₆ alkyl bound to asulfinyl group. Examples include methylsulfinyl, ethylsulfinyl, andn-propylsulfinyl.

Examples of the “aryl” include phenyl and naphthyl.

The “heteroaryl” means a five- or six-membered monocyclic heteroarylhaving one or more, preferably 1 to 3 heteroatoms, the same ordifferent, selected from the group consisting of an oxygen atom, anitrogen atom, and a sulfur atom, or a condensed-ring heteroaryl formedby the condensation of the monocyclic heteroaryl and the aryl, or by thecondensation of the monocyclic heteroaryls which may be the same ordifferent. Examples include pyrrolyl, furyl, thienyl, imidazolyl,pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isooxazolyl, triazolyl,tetrazolyl, oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl,1,3,4-thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,1,2,4-triazinyl, 1,3,5-triazinyl, indolyl, benzofuranyl, benzothienyl,benzoimidazolyl, benzopyrazolyl, benzooxazolyl, benzoisooxazolyl,benzothiazolyl, benzoisothiazolyl, indazolyl, purinyl, quinolyl,isoquinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl,cinnolinyl, pteridinyl, and pyrido[3,2-b]pyridyl.

The “aryl” or “heteroaryl” may be substituted with a substituentselected from the group consisting of hydroxy, cyano, halogen, C₁₋₆alkyl, halo C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, halo C₁₋₆ alkoxy,C₃₋₈ cycloalkoxy, amino, C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, halo C₁₋₆alkylamino, dihalo C₁₋₆ alkylamino, C₃₋₈ cycloalkylamino, di-C₃₋₈cycloalkylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, di-C₁₋₆ alkylcarbamoyl,halo C₁₋₆ alkylcarbamoyl, dihalo C₁₋₆ alkylcarbamoyl, C₃₋₈cycloalkylcarbamoyl, di-C₃₋₈ cycloalkylcarbamoyl, thiol, C₁₋₆ alkylthio,halo C₁₋₆ alkylthio, C₃₋₈ cycloalkylthio, C₁₋₆ alkylsulfinyl, halo C₁₋₆alkylsulfinyl, C₃₋₈ cycloalkylsulfinyl, C₁₋₆ alkylsulfonyl, halo C₁₋₆alkylsulfonyl, C₃₋₈ cycloalkylsulfonyl, C₁₋₆ alkylcarbonyl, halo C₁₋₆alkylcarbonyl, C₃₋₈ cycloalkylcarbonyl, C₁₋₆ alkoxycarbonyl, halo C₁₋₆alkoxycarbonyl, C₃₋₈ cycloalkoxycarbonyl, C₁₋₆ alkoxycarbonylamino, haloC₁₋₆ alkoxycarbonylamino, C₃₋₈ cycloalkoxycarbonylamino, C₁₋₆alkylcarbonylamino, halo C₁₋₆ alkylcarbonylamino, and C₃₋₈cycloalkylcarbonylamino.

The “arylcarbonyl” is a group with the aryl bound to carbonyl.

The “heteroarylcarbonyl” is a group with the heteroaryl bound tocarbonyl.

The “arylcarbonylamino” is a group in which one of the hydrogen atoms ofthe amino group is substituted with the arylcarbonyl.

The “heteroarylcarbonylamino” is a group in which one of the hydrogenatoms of the amino group is substituted with the heteroarylcarbonyl.

The “aryloxy” is a group with the aryl bound to an oxygen atom.

The “heteroaryloxy” is a group with the heteroaryl bound to an oxygenatom.

The “aryloxycarbonyl” is a group with the aryloxy bound to carbonyl.

The “heteroaryloxycarbonyl” is a group with the heteroaryloxy bound tocarbonyl.

The “aryloxycarbonylamino” is a group in which one of the hydrogen atomsof the amino group is substituted with the aryloxycarbonyl.

The “heteroaryloxycarbonylamino” is a group in which one of the hydrogenatoms of the amino group is substituted with the heteroaryloxycarbonyl.

The “arylsulfinyl” is a group with the aryl bound to a sulfinyl group.

The “heteroarylsulfinyl” is a group with the heteroaryl bound to asulfinyl group.

The “arylsulfonyl” is a group with the aryl bound to a sulfonyl group.

The “heteroarylsulfonyl” is a group with the heteroaryl bound to asulfonyl group.

The “arylsulfonylamino” is a group in which one of the hydrogen atoms ofthe amino group is substituted with the arylsulfonyl.

The “heteroarylsulfonylamino” is a group in which one of the hydrogenatoms of the amino group is substituted with the heteroarylsulfonyl.

The “aralkyl” means a group with the C₁₋₆ alkyl bound to the aryl.Examples include benzyl, 1-phenylethyl, 2-phenylethyl, 1-naphthylmethyl,and 2-naphthylmethyl.

The “heteroaralkyl” means a group with the C₁₋₆ alkyl bound to theheteroaryl.

The “aralkyloxy” means a group with the aralkyl bound to an oxygen atom.

The “heteroaralkyloxy” means a group with the heteroaralkyl bound to anoxygen atom.

The “heterocyclyl” is a saturated, partially saturated, or unsaturatedmonocyclic or bicyclic ring having 4 to 10 atoms that include 1 to 3hetero atoms selected from nitrogen, oxygen, and sulfur, wherein thering nitrogen atom may be substituted with a group selected from C₁₋₆alkyl, amino-C₁₋₆ alkyl, aryl, aryl-C₁₋₆ alkyl, and acyl, and whereinthe ring carbon atom may be substituted with C₁₋₆ alkyl, amino-C₁₋₆alkyl, aryl, aryl-C₁₋₆ alkyl, heteroaryl, C₁₋₆ alkoxy, hydroxy, or oxo.Examples include pyrrolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl,morpholinyl, piperazinyl, dioxolanyl, and tetrahydropyranyl.

A “salt” of a compound of the present invention means a pharmaceuticallyacceptable salt commonly used. For example, in the case of a carboxylgroup, the salt may be a base addition salt formed at the carboxylgroup. The salt may be an acid addition salt of amino group or the basicheterocyclic group.

Examples of the base addition salt include: alkali metal salts such assodium salt, and potassium salt; alkali-earth metal salts such ascalcium salt, and magnesium salt; ammonium salts; and organic aminesalts such as trimethylamine salt, triethylamine salt, dicyclohexylaminesalt, ethanolamine salt, diethanolamine salt, triethanolamine salt,procaine salt, and N,N′-dibenzylethylenediamine salt.

Examples of the acid addition salt include: inorganic acid salts such ashydrochloride, sulfate, nitrate, phosphate, and perchlorate; organicacid salts such as maleate, fumarate, tartrate, citrate, ascorbate, andtrifluoroacetate; and sulfonates such as methanesulfonate, isethionate,benzenesulfonate, and p-toluenesulfonate.

The following discloses a compound of the present invention in moredetail based on specific preferable examples of various symbols used inFormula (I).

The “arbitrary available substitution positions”, as that term is usedherein, refer to the position where a hydrogen atom chemicallyacceptable for substitution is present on carbon, nitrogen, oxygenand/or sulfur atoms, and at which substitution of the hydrogen atomcreates a chemically stable compound.

A compound of the present invention, depending on the type of thesubstituent or its salt form, may exist as a stereoisomer, such as anoptical isomer, a diastereomer, and a geometric isomer, or as atautomer. A compounds of the present invention encompass all suchstereoisomers, tautomers, and mixtures thereof

The present invention encompass various crystals, amorphous forms,salts, hydrates, and solvates of a compound of the present invention.

A prodrug of a compound of the present invention also falls within thescope of the present invention. Generally, such a prodrug is afunctional derivative of a compound of the present invention, easilyconvertible into a compound required in the body. Accordingly, in thetreatment of various diseases according to the present invention, theterm “administration” encompasses not only the administration of aspecific compound but the administration of a compound that convertsinto a specific compound in the body after being given to a patient.Routine means for the selection and production of a suitable prodrugderivative are described in, for example, Design of Prodrugs, ed. H.Bundgaard, Elsevier, 1985, the entire disclosure of which is herebyincorporated herein by reference. The metabolites of these compounds areinclusive of active compounds produced from a compound of the presentinvention in a biological environment, and such metabolites also fallwithin the scope of the present invention.

R¹ represents C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or heteroaryl, whereinthe alkyl, cycloalkyl, aryl, or heteroaryl may be substituted with asubstituent selected from the group consisting of hydroxy, cyano,carboxyl, sulfo, halogen, C₁₋₆ alkyl, halo C₁₋₆ alkyl, C₃₋₈ cycloalkyl,C₁₋₆ alkoxy, halo C₁₋₆ alkoxy, amino (the amino being optionallysubstituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls), carbamoyl(the carbamoyl being optionally substituted with 1 to 2 C₁₋₆ alkyls,aryls, or heteroaryls), sulfanyl (the sulfanyl being optionallysubstituted with one C₁₋₆ alkyl, aryl, or heteroaryl), C₁₋₆alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, C₁₋₆ alkylsulfonyl,arylsulfonyl, heteroarylsulfonyl, sulfamoyl (the sulfamoyl beingoptionally substituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls),C₁₋₆ alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino,C₁₋₆ alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C₁₋₆alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, carbamoylamino(the carbamoylamino being optionally substituted with 1 to 2 C₁₋₆alkyls, aryls, or heteroaryls), C₁₋₆ alkoxycarbonylamino,aryloxycarbonylamino, heteroaryloxycarbonylamino, C₁₋₆alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, aryl,heteroaryl, aralkyl, heteroaralkyl, aralkyloxy, and heteroaralkyloxy.

R¹ is preferably, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or heteroaryl,examples of which include those optionally substituted with asubstituent selected from the group consisting of halogen, C₁₋₆ alkyl,and C₁₋₆ alkoxy.

Specific examples of R¹ include methyl, ethyl, propyl, isopropyl, butyl,isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl,2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl,3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl,2-trifluoromethylphenyl, 3-trifluoromethylphenyl,4-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl,4-methoxyphenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl,pyrimidin-2-yl, pyrazin-2-yl, pyridazin-3-yl, 2-thienyl, 3-thienyl,1-methyl-1H-imidazol-4-yl, 5-methyl-1,3,4-thiadiazol-2-yl,1,3-thiazol-2-yl, 1,3-oxazol-2-yl, and 1,3,4-thiadiazol-2-yl.Preferably, it is recommended that R¹ be propyl, isopropyl, butyl,isobutyl, cyclopropyl, phenyl, 2-chlorophenyl, 3-chlorophenyl,4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl,2-trifluoromethylphenyl, 3-trifluoromethylphenyl,4-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl,4-methoxyphenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl,pyrimidin-2-yl, pyrazin-2-yl, pyridazin-3-yl, 2-thienyl, 3-thienyl,1-methyl-1H-imidazol-4-yl, 5-methyl-1,3,4-thiadiazol-2-yl,1,3-thiazol-2-yl, 1,3-oxazol-2-yl, or 1,3,4-thiadiazol-2-yl.

R² represents phenyl or heteroaryl, wherein the phenyl or heteroaryl maybe substituted with a substituent selected from the group consisting ofhydroxy, cyano, carboxyl, sulfo, halogen, C₁₋₆ alkyl, halo C₁₋₆ alkyl,C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, halo C₁₋₆ alkoxy, amino (the amino beingoptionally substituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls),carbamoyl (the carbamoyl being optionally substituted with 1 to 2 C₁₋₆alkyls, aryls, or heteroaryls), sulfanyl (the sulfanyl being optionallysubstituted with one C₁₋₆ alkyl, aryl, or heteroaryl), C₁₋₆alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, C₁₋₆ alkylsulfonyl,arylsulfonyl, heteroarylsulfonyl, sulfamoyl (the sulfamoyl beingoptionally substituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls),C₁₋₆alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, C₁₋₆alkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C₁₋₆ alkoxycarbonyl,aryloxycarbonyl, heteroaryloxycarbonyl, carbamoylamino (thecarbamoylamino being optionally substituted with 1 to 2 C₁₋₆ alkyls,aryls, or heteroaryls), C₁₋₆ alkoxycarbonylamino, aryloxycarbonylamino,heteroaryloxycarbonylamino, C₁₋₆ alkylcarbonylamino, arylcarbonylamino,heteroarylcarbonylamino, aryl (the aryl being optionally substitutedwith C₁₋₆ alkoxy), heteroaryl, aryloxy, heteroaryloxy, aralkyl,heteroaralkyl, aralkyloxy, and heteroaralkyloxy.

R² is preferably phenyl or heteroaryl, examples of which include thosesubstituted with a substituent selected from the group consisting ofhalogen, C₁₋₆ alkyl, halo C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, aryl(the aryl being optionally substituted with C₁₋₆ alkoxy), aralkyl, andaralkyloxy.

Specific examples of R² include phenyl, 2-methoxyphenyl,3-methoxyphenyl, 4-methoxyphenyl, 2-ethoxyphenyl, 3-ethoxyphenyl,4-ethoxyphenyl, 2-isopropoxyphenyl, 3-isopropoxyphenyl,4-isopropoxyphenyl, 2-isobutyloxyphenyl, 3-isobutyloxyphenyl,4-isobutyloxyphenyl, 2-cyclopropyloxyphenyl, 3-cyclopropyloxyphenyl,4-cyclopropyloxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl,2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-trifluoromethylphenyl,3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-phenoxyphenyl,3-phenoxyphenyl, 4-phenoxyphenyl, 2-benzyloxyphenyl, 3-benzyloxyphenyl,4-benzyloxyphenyl, 2-benzylphenyl, 3-benzylphenyl, 4-benzylphenyl,2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-isopropylphenyl,3-isopropylphenyl, 4-isopropylphenyl, 5-isopropoxyphenylpyridin-2-yl,6-isopropoxyphenylpyridin-3-yl, 5-isopropoxypyrimidin-2-yl,3-methoxypyridin-2-yl, 3-cyclopropyl-1H-pyrazol-5-yl, and5-isopropoxy-1H-pyrazol-3-yl. Preferably, it is recommended that R² bephenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl,3-chlorophenyl, 4-chlorophenyl, 2-methoxyphenyl, 3-methoxyphenyl,4-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl,2-isopropylphenyl, 3-isopropylphenyl, 4-isopropylphenyl,2-isopropoxyphenyl, 3-isopropoxyphenyl, 4-isopropoxyphenyl,2-benzylphenyl, 3-benzylphenyl, 4-benzylphenyl, 2-benzyloxyphenyl,3-benzyloxyphenyl, 4-benzyloxyphenyl, 5-isopropoxyphenylpyridin-2-yl,6-isopropoxyphenylpyridin-3-yl, 5-isopropoxypyrimidin-2-yl,3-methoxypyridin-2-yl, 3-cyclopropyl-1H-pyrazol-5-yl, or5-isopropoxy-1H-pyrazol-3-yl.

R³ represents a hydrogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aralkyl,heteroaralkyl, aryl, or heteroaryl, wherein the alkyl, cycloalkyl,aralkyl, aryl, or heteroaryl may be substituted with a substituentselected from the group consisting of halogen, C₁₋₆ alkyl, halo C₁₋₆alkyl, C₁₋₆ alkoxy, and halo C₁₋₆ alkoxy.

Specific examples of R³ include a hydrogen atom, methyl, ethyl, propyl,butyl, pentyl, hexyl, isopropyl, isobutyl, isopentyl, phenyl,pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, and benzyl.Preferable examples include a hydrogen atom, methyl, ethyl, propyl,isopropyl, phenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, and benzyl.Particularly, it is recommended that R³ be a hydrogen atom.

Z is selected from the group consisting of the following Formulae(II-1), (II-2), and (II-3).

wherein n1, n2, and n3 are 0, 1, or 2, respectively.

Z is preferably (II-1) or (II-2). When Z is (II-1), it is recommendedthat n1=0. When Z is (II-2), it is recommended that n2=1.

M₁, M₂, M₃, and M₄ independently represent a hydrogen atom, or C₁₋₆alkyl optionally substituted with halogen; or M₁, together with M₂, M₃,or M₄, forms —CH₂— or —CH₂—CH₂—; or M₄, together with M₂, forms —CH₂— or—CH₂—CH₂—;

provided that R³ is a hydrogen atom, then any two of M₁, M₂, M₃, and M₄together form —CH₂— or —CH₂—CH₂—.

Specific examples of M₁, M₂, M₃, and M₄ include a hydrogen atom, methyl,ethyl, n-propyl, n-butyl, chloromethyl, fluoromethyl, andtrifluoromethyl. Alternatively, M₁, together with M₂, M₃, or M₄, forms—CH₂— or —CH₂—CH₂—, or M₄, together with M₂, forms —CH₂— or —CH₂—CH₂—.

Examples of specific combinations of M₁, M₂, M₃, and M₄ include:

(1) M₁, together with M₂, forming —CH₂— or —CH₂—CH₂—, and M₃ and M₄being independently a hydrogen atom, or C₁₋₆ alkyl optionallysubstituted with halogen;

(2) M₁, together with M₃, forming —CH₂— or —CH₂—CH₂—, and M₂ and M₄being independently a hydrogen atom, or C₁₋₆ alkyl optionallysubstituted with halogen;

(3) M₁, together with M₄, forming —CH₂— or —CH₂—CH₂—, and M₁ and M₂being independently a hydrogen atom, or C₁₋₆ alkyl optionallysubstituted with halogen;

(4) M₄, together with M₂, forming —CH₂— or —CH₂—CH₂—, and M₁ and M₃being independently a hydrogen atom, or C₁₋₆ alkyl optionallysubstituted with halogen; and

(5) M₁, M₂, M₃, and M₄ all being hydrogen atoms.

Preferable combinations of M₁, M₂, M₃, and M₄ include:

M₁, together with M₃, forming —CH₂— or —CH₂—CH₂—, and M₂ and M₄ beingindependently a hydrogen atom, or C₁₋₆ alkyl optionally substituted withhalogen;

M₁, together with M₂, forming —CH₂— or —CH₂—CH₂—, and M₃ and M₄ beingindependently a hydrogen atom, or C₁₋₆ alkyl optionally substituted withhalogen; and

M₁, M₂, M₃, and M₄ all being hydrogen atoms.

Particularly, it is recommended that:

M₁, together with M₂, form —CH₂—CH₂—, and M₃ and M₄ each represent ahydrogen atom;

M₁, together with M₃, form —CH₂—CH₂—, and M₂ and M₄ each represent ahydrogen atom; or

M₁, M₂, M₃, and M₄ all represent hydrogen atoms.

A compound of the present invention may include one or more asymmetriccenters, and can therefore occur as a racemate or a racemic mixture, asingle enantiomer, a mixture of diastereomers, or an individualdiastereomer. Each such asymmetric center will independently produce twooptical isomers, and the present invention encompass all possibleoptical isomers and diastereomers, either as a mixture, a pure compound,or a partially purified compound.

Preferably, it is recommended that the compound of Formula (I) is:

-   (1R**,4S**,6R**)-N-(4-isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide;-   (1S**,4R**,6S**)-N-(4-isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide;-   (1R*,4S*,6R*)-2-(butylsulfonyl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azabicyclo[2.2.2]octane-6-carboxamide;-   (1R*,4S*,6R*)-N-(5-isopropoxypyridin-2-yl)-2-(pyridin-2-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide;-   (1R**,4S**,6R**)-N-(5-isopropoxypyridin-2-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide;-   (1S**,4R**,6S**)-N-(5-isopropoxypyridin-2-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide;-   2-methoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide;-   4-isopropoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide;-   4-isopropoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)benzamide;-   5-isopropoxy-N-{[3-phenyl-1-(propylsulfonyl)piperidin-3-yl]methyl}pyridine-2-carboxamide;-   5-isopropoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}pyridine-2-carboxamide;-   5-isopropoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)pyridine-2-carboxamide;-   4-isopropoxy-N-{[3-methyl-1-(phenylsulfonyl)piperidin-3-yl]methyl}benzamide;-   4-isopropoxy-N-{[3-methyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide;-   N-{[3-ethyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}-4-isopropoxybenzamide;-   N-({3-ethyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-3-yl}methyl)-4-isopropoxybenzamide;-   3-isobutyl-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide;-   3-ethyl-N-(5-isopropoxypyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-3-carboxamide;-   3-ethyl-N-(5-isopropoxy-1H-pyrazol-3-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-3-carboxamide;    or-   (1R*,4S*,6R*)-N-(5-isopropoxy-1H-pyrazol-3-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide.

Producing Methods of a Compound of Formula (I)

A compound according to the present invention can be produced by methodsdescribed in, for example, the Producing Method and Example Sectionsbelow. It should be noted, however, that producing methods of a compoundaccording to the present invention are not limited to the examplesbelow.

Producing Method 1

A compound of Formula (I) with Z=(II-1), namely a compound of Formula(I-1) can be prepared according to the following method.

[The Symbols in the Formula are as Defined Above.] Step 1

Compound 1 is allowed to react with Compound 2 in an organic solvent inthe presence of a base to obtain Compound 3.

It is recommended that Compound 2 be used, for example, in 1 to 5 moles,preferably 1 to 3 moles per mole of Compound 1.

Examples of the base include triethylamine, diisopropylethylamine, andpyridine. It is recommended that the base be used, for example, in 1 to10 moles, preferably 1 to 3 moles per mole of Compound 1.

Examples of the organic solvent include methylene chloride, chloroform,toluene, tetrahydrofuran (hereinafter, “THF”), 1,4-dioxane, dimethylsulfoxide (hereinafter, “DMSO”), ethyl acetate, and acetonitrile.

It is recommended that the reaction temperature be, for example, 0 to60° C., preferably 0 to 30° C. The reaction generally completes in 1 to24 hours.

The Compound 3 obtained as above can easily be isolated and purifiedusing common separation means, for example, such as solvent extraction,recrystallization, column chromatography, and preparative thin-layerchromatography (this method can be applied to the following methods).

Examples of Compound 1 include ethyl 3-ethylpiperidine-3-carboxylate,ethyl piperidine-3-carboxylate, and methyl2-azabicyclo[2.2.2]octane-6-carboxylate. Examples of Compound 2 includemethanesulfonyl chloride, ethanesulfonyl chloride, propanesulfonylchloride, butanesulfonyl chloride, and benzenesulfonyl chloride.

Step 2

Compound 3 is subjected to hydrolysis using a known method to obtainCompound 4.

Although the method is not particularly limited, hydrolysis can beperformed in an organic solvent, for example, such as methanol andethanol, in a temperature range of from room temperature to the boilingpoint of the solvent, using a sodium hydroxide solution, a potassiumhydroxide solution, or the like.

Step 3

Compound 4 and Compound 5 are subjected to an amidation reaction toobtain a compound of Formula (I-1).

Amidation can be performed using known methods. For example, Compound 4and Compound 5 may react with each other in the presence of a condensingagent, or the carboxylic acid moiety of Compound 4 may be activated toform a reactive derivative using a known method, and the derivative mayundergo amidation with Compound 5. (For details of these methods, seePepuchido Gosei no Kiso to Jikken, Nobuo Izumiya, et al., Maruzen Co.,Ltd., 1983.)

The reaction using a condensing agent can be performed as follows, forexample.

Compound 4 and Compound 5 are condensed in a reaction solvent using acondensing agent to obtain the compound of Formula (I-1).

The amount of Compound 5 used is, for example, 1 to 3 moles per mole ofCompound 4.

Examples of the condensing agent include dicyclohexylcarbodiimide,1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, andO-(7-azabenzotriazol-1-yl)-1,1,3,3-tetra-methyluroniumhexafluorophosphate(hereinafter, “HATU”). The amount used is, for example, 1 to 3 moles permole of Compound 4.

To promote reaction, hydroxybenzotriazole (hereinafter, “HOBT”) or thelike may be added to the reaction system. The amount of HOBT used is,for example, 1 to 3 moles per mole of Compound 4.

Examples of the reaction solvent include THF, 1,4-dioxane,N,N-dimethylformamide (hereinafter, “DMF”), DMSO, dichloromethane,chloroform, pyridine, and a mixed solvent thereof

The reaction temperature is, for example, 20 to 100° C. The recommendedreaction temperature is preferably 20 to 50° C. The reaction generallycompletes in 1 to 24 hours.

Examples of Compound 5 include aniline, 2-methoxyaniline,3-methoxyaniline, 4-methoxyaniline, and3-cyclopropyl-1H-pyrazole-5-amine.

Producing Method 2

Producing Method 2 is an alternative synthesis method of the compound ofFormula (I-1) using Compound 1 as the raw material.

[In the Formula, P Represents a Protective Group; the Other Symbols areas Defined Above.] Step 4

A protective group is introduced into the amino group of Compound 1 toobtain Compound 6. The protective group can be introduced according tothe method described in Protective Groups in Organic Synthesis, T. W.Greene, John Wiley & Sons, 1981, or using similar methods. Examples ofthe protective group include tert-butyl oxycarbonyl, benzyloxycarbonyl,and p-methoxybenzyloxycarbonyl.

Step 5

The ester of Compound 6 is hydrolyzed to obtain Compound 7. Although themethod is not particularly limited, hydrolysis can be performed in anorganic solvent, for example, such as methanol and ethanol, in atemperature range of from room temperature to the boiling point of thesolvent, using a sodium hydroxide solution, a potassium hydroxidesolution, or the like.

Steps 6 and 7

Compound 7 and Compound 5 are allowed to react according to Step 3 ofProducing Method 1 to obtain Compound 8, followed by removing theprotective group to obtain Compound 9.

The protective group of Compound 9 can be removed using, for example,the method described in Protective Groups in Organic Synthesis.

Step 8

Compound 9 is condensed with Compound 2 according to Step 1 of ProducingMethod 1 to obtain the compound of Formula (I-1).

Producing Method 3

Producing Method 3 is a method for producing a compound of Formula (I)with Z=(II-2), specifically a compound of Formula (I-2).

[The Symbols in the Formula are as Defined Above] Step 9

Compound 6′ (R³═H in Compound 6, and as such R³ excludes hydrogen) istreated with a base in a reaction solvent, and adding Compound 10 to thereaction system to obtain Compound 6.

Examples of the base include lithium diisopropylamide (hereinafter,“LDA”). The amount of base used is, for example, 1 to 2 moles per moleof Compound 6′.

Examples of the reaction solvent include THF.

The process temperature is, for example, −78 to 20° C., and the reactionis generally performed for 1 to 2 hours. Compound 10 is then added tothe reaction mixture to perform a substitution reaction.

The amount of Compound 10 used is, for example, 1 to 10 moles per moleof Compound 6′. The recommended amount is preferably 1 to 3 moles.

The reaction temperature is, for example, −78 to 20° C., and thereaction generally completes in 1 to 3 hours.

Examples of Compound 10 include methyl iodide, ethyl iodide, isopropylbromide, and benzyl bromide.

Step 10

Compound 11 is obtained by the reduction of the ester moiety of Compound6 using a reducing agent such as lithium aluminum hydride and sodiumborohydride, using a known method.

Step 11

Compound 11 and phthalimide are condensed by the Mitsunobu reaction toobtain Compound 12.

Specifically, Compound 12 is obtained by the condensation of Compound 11and phthalimide in the reaction solvent in the presence of azo compoundssuch as dialkyl azodicarboxylate or 1,1′-(azodicarbonyl)diamide, andorganophosphorus compounds such as triarylphosphine ortrialkylphosphine.

Examples of the azo compound include dimethyl azodicarboxylate, diethylazodicarboxylate (hereinafter, “DEAD”), diisopropyl azodicarboxylate(hereinafter, “DIAD”), and 1,1′-(azodicarbonyl)dipiperidide(hereinafter, “DPPA”). Examples of the triarylphosphine includetriphenylphosphine, and tritolylphosphine. Examples of thetrialkylphosphine include triethylphosphine, and tributylphosphine. Acombination of diisopropyl azodicarboxylate and triphenylphosphine, or acombination of 1,1′-(azodicarbonyl)dipiperidide and tributylphosphine isrecommended.

The amount of phthalimide used is, for example, 1 to 10 moles per moleof Compound 11. The recommended amount is preferably 1 to 1.5 moles.

The amount of azo compound used is, for example, 1 to 3 moles per moleof Compound 11. The recommended amount is preferably 1 to 1.5 moles. Theamount of organophosphorus compound used is, for example, 1 to 3 molesper mole of phthalimide. The recommended amount is preferably 1 to 1.5moles.

Examples of the reaction solvent include: halocarbons such as methylenechloride, chloroform, dichloroethane, and carbon tetrachloride;aliphatic hydrocarbons such as n-heptane and n-hexane; aromatichydrocarbons such as benzene, toluene, and xylene; ethers such asdiethyl ether, THF, 1,4-dioxane, and ethylene glycol dimethyl ether;esters such as methyl acetate, and ethyl acetate; acetonitrile;N-methylpyrrolidone (hereinafter, “NMP”); DMF; DMSO; and a mixed solventthereof

The reaction temperature is, for example, 0° C. to 100° C. Therecommended reaction temperature is preferably 0° C. to 50° C. Thereaction generally completes in 2 to 24 hours.

Step 12

Compound 12 is subjected to a hydrazine treatment in the reactionsolvent to obtain Compound 13.

The amount of hydrazine used is, for example, 1 to 10 moles per mole ofCompound 12. The recommended amount is preferably 1 to 5 moles.

Examples of the reaction solvent include methanol and ethanol.

The reaction temperature is, for example, 0 to 60° C., preferably 0 to30° C. The reaction generally completes in 1 to 24 hours.

Steps 13 to 15

The Compound 13 obtained as above is condensed with Compound 14according to Step 3 to obtain Compound 15. The protective group ofCompound 15 is removed according to Step 7 to obtain Compound 16, whichis then allowed to react with Compound 2 according to Step 1 to obtainthe compound of Formula (I-2).

Examples of Compound 14 include 2-methoxybenzoic acid, 3-methoxybenzoicacid, 4-methoxybenzoic acid, and 4-isopropoxybenzoic acid.

Producing Method 4

Producing Method 4 is a method for producing the compound of Formula(I-2) using Compound 3 as the raw material.

[The Symbols in the Formula are as Defined Above.] Step 16

Compound 3 is reduced using a reducing agent to obtain Compound 17. Thereducing method is according to Step 10.

Steps 17 and 18

Compound 17 is allowed to react with phthalimide according to Step 11 toobtain Compound 18. After the hydrazine treatment of Compound 18 as inStep 12, Compound 19 is obtained.

Step 19

Compound 19 is condensed with Compound 14 according to Step 3 to obtainthe compound of Formula (I-2).

Producing Method 5 is a method for producing the compound of Formula(I-2′).

[The Symbols in the Formula are as Defined Above.] Step 20-1

Compound 20′ is obtained by the Curtius rearrangement reaction ofCompound 4.

Specifically, Compound 20′ is obtained by the reaction of Compound 4with diphenylphosphoryl azide (DPPA) in a reaction solvent in thepresence of a base (see Shioiri, T.; Ninomiya, K.; Yamada, S, J. Am.Chem. Soc., 1972, Vol. 94, pp. 6203-6205).

Examples of the base include triethylamine, and diisopropylethylamine.The amount of base used is, for example, 1 to 4 moles per mole ofCompound 4. The recommended amount is preferably 1 to 2 moles.

The amount of DPPA used is, for example, 1 to 4 moles per mole ofCompound 4.

The recommended amount is preferably 1 to 2 moles.

Examples of the reaction solvent include THF,1,4-dioxane, andtert-butanol.

The reaction temperature is, for example, 20 to 100° C., preferably 20to 80° C. The reaction generally completes in 1 to 24 hours.

Step 20-2

Compound 20′ is treated with an acid using a 1,4-dioxane solution ofexcess hydrochloric acid to obtain Compound 20.

The reaction temperature is, for example, 20 to 120° C., preferably 20to 80° C. The reaction generally completes in 1 to 24 hours.

Step 21

Compound 20 is condensed with Compound 14 according to Step 3 to obtainthe compound of Formula (I-2′).

Producing Method 6

Producing Method 6 is a method for producing a compound of Formula (I)with Z=(II-3), namely a compound of Formula (I-3).

[The Symbols in the Formula are as Defined Above.] Step 22

Compound 13 is reacted with Compound 21 in a reaction solvent in thepresence of a base to obtain Compound 22.

Examples of Compound 21 include phenyl isocyanate, and 4-methoxyphenylisocyanate. The amount used is, for example, 1 to 4 moles per mole ofCompound 13. The recommended amount is preferably 1 to 2 moles.

Examples of the base include triethylamine, diisopropylethylamine, andpyridine. The amount of base used is, for example, 1 to 5 moles per moleof Compound 13. The recommended amount is preferably 1 to 3 moles.

Examples of the reaction solvent include pyridine, THF, 1,4-dioxane,methylene chloride, chloroform, and DMSO.

The reaction temperature is, for example, 0 to 100° C., preferably 0 to50° C. The reaction generally completes in 1 to 24 hours.

Steps 23 and 24

The protective group of Compound 22 is deprotected according to Step 4to obtain Compound 23. After condensation with Compound 2 according toStep 2, the compound of Formula (I-3) is obtained.

When the reactants in the reactions of the Producing Methods 1 to 6include groups not involved in the reaction, such as amino, hydroxy, andcarboxyl, the reaction may be performed after appropriately protectingthe amino, hydroxy, or carboxyl with the protective group, which may beremoved after the reaction.

Examples of the protective group for the amino include: aralkyls such asbenzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl,p-nitrobenzyl, benzhydryl, and trityl; C₁₋₆alkanoyls such as formyl,acetyl, propionyl, butyryl, and pivaloyl; benzoyls; arylalkanoyls suchas phenylacetyl and phenoxyacetyl; C₁₋₆ alkoxycarbonyls such asmethoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, andtert-butoxycarbonyl; aralkyloxycarbonyls such as benzyloxycarbonyl,p-nitrobenzyloxycarbonyl, and phenethyloxycarbonyl; and C₁₋₆ alkylsilylssuch as trimethylsilyl, and tert-butyl dimethylsilyl. Particularlypreferable examples include acetyl, pivaloyl, benzoyl, ethoxycarbonyl,and tert-butoxycarbonyl.

Examples of the protective group for the hydroxy include: substitutedsilyls such as trimethylsilyl, tert-butyl dimethylsilyl, and tert-butyldiphenylsilyl; lower alkoxymethyls such as methoxymethyl, and2-methoxyethoxymethyl; tetrahydropyranyl; aralkyls such as benzyl, andp-methoxybenzyl; acyls such as formyl and acetyl; and benzoyls.

Examples of the protective group for the carboxyl include: C₁₋₆ alkylssuch as methyl, ethyl, propyl, isopropyl, and tert-butyl; C₁₋₆haloalkyls such as 2,2,2-trichloroethyl; C₁₋₆ alkenyls such as2-propenyl; and aralkyls such as benzyl, p-methoxybenzyl, p-nitrobenzyl,benzhydryl, and trityl. Particularly preferable examples include methyl,ethyl, tert-butyl, 2-propenyl, benzyl, p-methoxybenzyl, and benzhydryl.

The protective group can be introduced and removed according to themethod described in Protective Groups in Organic Synthesis, or usingsimilar methods.

The compounds of Formulae (I-1), (I-2), and (I-3) thus obtained can beeasily isolated and purified using common separation means, for example,such as solvent extraction, recrystallization, column chromatography,and preparative thin-layer chromatography.

The compound can be turned into a pharmaceutically acceptable salt usingan ordinary method. The conversion from the salt to a free compound canalso be performed according an ordinary method.

The usefulness of a compound according to the present invention as amedicament is demonstrated by the following pharmacological testexamples.

Pharmacological Test Example 1 LCE Enzymatic Activity Inhibition Test

A test compound was dissolved in dimethylsulfoxide (DMSO) at 10 mM, andthen, the resulting solution was further diluted with DMSO to prepare a1000-fold stock solution having a concentration 1000 times higher thanthe concentration to be evaluated. An LCE enzymatic activity inhibitiontest was carried out by a modified method of Moon (J. Biol. Chem., Vol.276, pp. 45358-45366, (2001)) et al. That is, the diluted test compoundwas added to a 96-well assay plate (Corning, 96-Well Assay Block) in anamount of 1.0 μL per well, and thereafter, 50 μL of a phosphate buffersolution (a 100 mM potassium phosphate buffer solution (pH 6.5)), 25 μLof a substrate solution (a 100 mM potassium phosphate buffer solution(pH 6.5), 4.0 μM rotenone, 80 μM fatty acid-free bovine serum albumin,160 μM palmitoyl-CoA, 80 μM malonyl-CoA, 3.5 μM [¹⁴C]-malonyl-CoA (1.92GBq/mmol, manufactured by Amersham, Inc.)) was added to each well, andfurther, 25 μL of an enzyme solution (a 100 mM potassium phosphatebuffer solution (pH 6.5), 100 μg/mL human LCE) was added thereto. Then,the upper part of the plate was hermetically closed with a seal member,and the plate was incubated at 37° C. for 90 minutes while gentlyshaking and stirring. Thereafter, to each well, 100 μL of 5 N HCl wasadded and the assay plate was stirred at room temperature for 5 minutes,whereby the enzymatic reaction was stopped and also acyl-CoA washydrolyzed. Thereafter, the enzymatic reaction solution in each well wasadsorbed to each well of a 96-well GF/C filter plate (PerkinElmer,Unifilter 96GF/C) through which water had been passed in advance, andthen, each well was washed with water to remove unadsorbed malonyl-CoAand the GF/C filter plate was dried at 50° C. for 60 minutes.Thereafter, to each well, 30 μL of a scintillator (PerkinElmer,Microscinti 0) was added and the upper part of the plate was sealed, andthe radioactivity of the fixed [¹⁴C] was measured using a microplatescintillation counter (PerkinElmer, Top Count) from which the enzymaticactivity was determined. The human LCE enzyme inhibitory activity of thetest compound was calculated using the radioactivity obtained from awell to which DMSO containing no test compound is added as a control.When the activities of the compounds of the invention were examinedusing this assay, these compounds inhibited the activity of human LCE.The results are shown in Table 1.

TABLE 1 Example Number Name IC₅₀ (nM) 26(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4- 268yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide 42(1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)- 1552-azabicyclo[2.2.2]octane-6-carboxamide 47(1R*,4S*,6R*)-N-(5-Isopropoxypyridin-2-yl)-2-(pyridin-2- 19ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide 48(1R*,4S*,6R*)-N-(5-isopropoxypyridin-2-yl)-2-[(1-methyl-1H- 159imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide 642-Methoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3- 20yl]methyl}benzamide 734-Isopropoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3- 3.7yl]methyl}benzamide 744-Isopropoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3- 17.4phenylpiperidin-3-yl}methyl)benzamide 765-Isopropoxy-N-{[3-phenyl-1-(propylsulfonyl)piperidin-3- 44yl]methyl}pyridine-2-carboxamide 785-Isopropoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3- 14yl]methyl}pyridine-2-carboxamide 795-Isopropoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3- 49phenylpiperidin-3-yl}methyl)pyridine-2-carboxamide 814-Isopropoxy-N-{[3-methyl-1-(phenylsulfonyl)piperidin-3- 51yl]methyl}benzamide 824-Isopropoxy-N-{[3-methyl-1-(pyridin-2-ylsulfonyl)piperidin-3- 60yl]methyl}benzamide 85N-{[3-Ethyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}-4- 14isopropoxybenzamide 86N-({3-Ethyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-3- 284yl}methyl)-4-isopropoxybenzamide 983-Isobutyl-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3- 12phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide 1033-Ethyl-N-(5-isopropoxypyridin-2-yl)-1-[(1-methyl-1H-imidazol-4- 35yl)sulfonyl]piperidine-3-carboxamide 1043-Ethyl-N-(5-isopropoxy-1H-pyrazol-3-yl)-1-[(1-methyl-1H-imidazol- 384-yl)sulfonyl]piperidine-3-carboxamide 105(1R*,4S*,6R*)-N-(5-Isopropoxy-1H-pyrazol-3-yl)-2-[(1-methyl-1H- 132imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

A compound according to the present invention can be orally orparenterally administered, and can be prepared into a suitableadministration form to provide a preventive or remedy for diseases suchas cardiovascular disease, including, for example, hypertension, angina,heart failure, myocardial infarction, stroke, claudication, diabeticnephropathy, diabetic retinopathy, failing vision, electrolyteabnormalities, and atherosclerosis; central neurologic disease,including, for example, bulimia, and diabetic neuropathy; metabolicdisease, including, for example, metabolic syndrome, obesity, diabetesmellitus, insulin resistance, hyperlipidemia, hypercholesteremia,neutral fat hyperlipaemia, dyslipidemia, non-alcoholic fatty liver,abnormal hormone secretion, gout, and fatty liver; reproductive disease,including, for example, menstrual disturbance, and sexual dysfunction;digestive disease, including liver dysfunction, pancreatitis,cholecystitis, and gastroesophageal reflux; respiratory disease,including obesity-hypoventilation syndrome (Pickwickian syndrome), andsleep apnea; bacterial, fungal, or parasitic infectious disease;malignant neoplasm; and inflammatory disease, including arthritis, andskin ulcer.

In one aspect, the present invention provides a method of treatment orprevention of disease, illness, or conditions attributed to LCEabnormalities, wherein a therapeutically or prophylactically effectiveamount a compound of the present invention is administered to a subjectin need thereof

In another aspect, the present invention provides a method of treatmentor prevention of metabolic syndrome, fatty liver, hyperlipidemia,dyslipidemia, non-alcoholic fatty liver, obesity, diabetes mellitus,bulimia, malignant neoplasm, or infectious disease, wherein atherapeutically or prophylactically effective amount a compound of thepresent invention is administered to a subject in need thereof

In another aspect, the present invention provides a method of treatmentor prevention of diabetes mellitus, wherein a therapeutically orprophylactically effective amount a compound of the present invention isadministered to a subject in need thereof

In another aspect, the present invention provides a method of treatmentor prevention of obesity, wherein a therapeutically or prophylacticallyeffective amount a compound of the present invention is administered toa subject in need thereof

In another aspect, the present invention provides at method of treatmentor prevention of an obesity-related disease selected from the groupconsisting of overeating, bulimia, hypertension, rise in plasma insulinlevel, insulin resistance, hyperlipidemia, endometrial cancer, breastcancer, prostate cancer, colon cancer, kidney cancer, osteoarthritis,obstructive sleep apnea syndrome, heart disease, abnormal cardiacrhythm, cardiac arrhythmia, myocardial infarction, congestive heartfailure, coronary heart disease, sudden death, stroke, polycysticovarian disease, craniopharingioma, metabolic syndrome, insulinresistance syndrome, sexual and reproductive dysfunction, infertility,hypogonadism, hirsutism, obesity-related gastroesophageal reflux,obesity-hypoventilation syndrome (Pickwickian syndrome), inflammation,systemic vasculitis, atherosclerosis, hypercholesteremia, hyperuricemia,lower back pain, inflammation, systemic vasculitis, atherosclerosis,hypercholesteremia, hyperuricemia, lower back pain, cholecystopathy,gout, constipation, irritable bowel syndrome, inflammatory bowelsyndrome, hearthypertrophy, and left ventricle hypertrophy, wherein atherapeutically or prophylactically effective amount a compound of thepresent invention is administered to a subject in need thereof

In another aspect, the present invention provides a method of treatmentor prevention of hyperlipidemia or dyslipidemia, wherein atherapeutically or prophylactically effective amount a compound of thepresent invention is administered to a subject in need thereof.

In another aspect, the present invention provides a caloric intakemethod, wherein a therapeutically or prophylactically effective amount acompound of the present invention is administered to a subject in needthereof.

In another aspect, the present invention provides a method for reducingfood intake, wherein a therapeutically or prophylactically effectiveamount a compound of the present invention is administered to a subjectin need thereof.

In another aspect, the present invention provides a method forincreasing satiety, wherein a therapeutically or prophylacticallyeffective amount a compound of the present invention is administered toa subject in need thereof.

In another aspect, the present invention provides a method for reducingappetite, wherein a therapeutically or prophylactically effective amounta compound of the present invention is administered to a subject in needthereof.

The present invention also relates to a method of treatment orprevention of obesity, wherein a compound according to the presentinvention is administered in combination with a therapeutically orprophylactically effective amount of other drugs known to be useful forthe treatment or prevention of the conditions to be treated orprevented.

The present invention also relates to a method of treatment orprevention of diabetes mellitus, wherein a compound according to thepresent invention is administered in combination with a therapeuticallyor prophylactically effective amount of other drugs known to be usefulfor the treatment or prevention of the conditions to be treated orprevented.

The present invention also relates to a method of treatment orprevention of hyperlipidemia or dyslipidemia, wherein a compound (I)according to the present invention or a pharmaceutically acceptable saltthereof is administered in combination with a therapeutically orprophylactically effective amount of other drugs known to be useful forthe treatment or prevention of the conditions to be treated orprevented.

In another aspect, the present invention provides a pharmaceuticalcomposition which contains a compound according to the presentinvention, and a pharmaceutically acceptable carrier.

In another aspect, the present invention relates to a compound of thepresent invention used as a medicament.

In another aspect, the present invention relates to use of a compound ofthe present invention for the production of medicaments useful for thetreatment, prevention, or suppression of the LCE-associated disease.

In another aspect, the present invention relates to use of a compound ofthe present invention for the production of medicaments useful for thetreatment or prevention of metabolic syndrome, hyperlipidemia,dyslipidemia, non-alcoholic fatty liver, obesity, diabetes mellitus,bulimia, malignant neoplasm, or infectious disease in a subject in needthereof

In another aspect, the present invention relates to use of a compound ofthe present invention for the production of medicaments useful for thetreatment or prevention of obesity in a subject in need thereof.

In another aspect, the present invention relates to use of a compound ofthe present invention for the production of medicaments useful for thetreatment or prevention of diabetes mellitus in a subject in needthereof.

In another aspect, the present invention relates to use of a compound ofthe present invention for the production of medicaments useful for thetreatment or prevention of hyperlipidemia or dyslipidemia in a subjectin need thereof

In another aspect, the present invention relates to use of atherapeutically effective amount of a compound of the present invention,and a therapeutically effective amount of a drug or a pharmaceuticallyacceptable salt thereof selected from the group consisting of insulinresistance improving agent, insulin analogue, sulfonylureas,α-glucosidase inhibitor, dipeptidyl peptidase 4 (DPP-4 or DP-IV)inhibitor, glucagon-like peptide 1 (GLP-1) agonist, HMG-CoA reductaseinhibitor, serotonin-like substance, β3-adrenaline receptor agonist,neuropeptide Y1 antagonist, neuropeptide Y2 agonist, neuropeptide Y5antagonist, pancreatic lipase inhibitor, cannabinoid CB1 receptorantagonist or inverse agonist, melanin concentrating hormone receptoragonist, melanocortin 4 receptor agonist, bombesin receptor subtype-3agonist, ghrelin antagonist, PYY, PYY₃₋₃₆, and NK-1 antagonist, whereinthe use is for the production of medicaments useful for the treatment,control, or prevention of obesity, diabetes mellitus, diabetesmellitus-related disease, or obesity-related disease in a subject inneed thereof

In another aspect, the present invention relates to simultaneous orseparate use of a therapeutically effective amount of a compound of thepresent invention, and a therapeutically effective amount of a drug or apharmaceutically acceptable salt thereof selected from the groupconsisting of insulin resistance improving agent, insulin analogue,sulfonylureas, α-glucosidase inhibitor, dipeptidyl peptidase 4 (DPP-4 orDP-IV) inhibitor, glucagon-like peptide 1 (GLP-1) agonist, HMG-CoAreductase inhibitor, serotonin-like substance, β3-adrenaline receptoragonist, neuropeptide Y1 antagonist, neuropeptide Y2 agonist,neuropeptide Y5 antagonist, pancreatic lipase inhibitor, cannabinoid CB1receptor antagonist or inverse agonist, melanin concentrating hormonereceptor agonist, melanocortin 4 receptor agonist, bombesin receptorsubtype-3 agonist, ghrelin antagonist, PYY, PYY₃₋₃₆, and NK-1antagonist, for the production of medicaments useful for the treatmentor prevention of obesity, diabetes mellitus, diabetes mellitus-relateddisease, or obesity-related disease.

In another aspect, the present invention relates to a combinedpreparation product for simultaneous, separate, or successive use inobesity, diabetes mellitus, diabetes mellitus-related disease, orobesity-related disease, wherein the preparation includes atherapeutically effective amount of a compound of the present invention,and a therapeutically effective amount of a drug or a pharmaceuticallyacceptable salt thereof selected from the group consisting of insulinresistance improving agent, insulin analogue, sulfonylureas,α-glucosidase inhibitor, dipeptidyl peptidase 4 (DPP-4 or DP-IV)inhibitor, glucagon-like peptide 1 (GLP-1) agonist, HMG-CoA reductaseinhibitor, serotonin-like substance, β3-adrenaline receptor agonist,neuropeptide Y1 antagonist, neuropeptide Y2 agonist, neuropeptide Y5antagonist, pancreatic lipase inhibitor, cannabinoid CB1 receptorantagonist or inverse agonist, melanin concentrating hormone receptoragonist, melanocortin 4 receptor agonist, bombesin receptor subtype-3agonist, ghrelin antagonist, PYY, PYY₃₋₃₆, and NK-1 antagonist.

In another aspect, the present invention relates to use of atherapeutically effective amount of a compound of the present invention,and a therapeutically effective amount of a drug or a pharmaceuticallyacceptable salt thereof selected from the group consisting ofsimvastatin, mevastatin, ezetimibe, atorvastatin, sitagliptin,metformin, sibutramine, orlistat, Qnexa (trade name), and phentermine,wherein the use is for the production of medicaments useful for thetreatment, control, or prevention of obesity, diabetes mellitus,diabetes mellitus-related disease, or obesity-related disease in asubject in need thereof

In clinical use of a compound of the present invention, the compound maybe administered after being prepared into various preparations byaddition of pharmaceutically acceptable additives, depending upon theadministration form. In this case, a variety of additives commonly usedin the field of pharmaceuticals can be used. Examples include gelatin,lactose, sucrose, titanium oxide, starch, microcrystalline cellulose,methylated cellulose, hydroxypropylmethyl cellulose, carboxymethylcellulose, cornstarch, microcrystalline wax, white vaseline, magnesiumaluminometasilicate, anhydrous calcium phosphate, citric acid, trisodiumcitrate, hydroxypropyl cellulose, sorbitol, sorbitan fatty acid ester,polysorbate, sucrose fatty acid ester, polyoxyethylene, hydrogenatedcastor oil, polyvinyl pyrrolidone, magnesium stearate, palmitoleic acid,light anhydrous silicic acid, talc, vegetable oil, benzyl alcohol, gumarabic, propylene glycol, polyalkylene glycol, cyclodextrin, andhydroxypropylcyclodextrin.

Examples of the dosage form prepared as a mixture with the additiveinclude: solid preparations such as a tablet, a capsule formulation, agranule, a powder, and a suppository; and liquid preparations such as asyrup, an elixir, and an injection. These can be prepared according tomethods commonly used in the field of pharmaceuticals. The liquidpreparation may be prepared by being dissolved or suspended in water orother suitable media before use. Specifically, the injection may beprepared by being dissolved or suspended in physiological saline orglucose solution as required, and may further include buffer orpreservative.

The compound of the invention is effective for plants and animals inneed of treatment with the compound, including humans and other mammals.Preferred examples of mammals are humans, and they may be male orfemale. The mammals other than humans are, for example, companionanimals such as dogs, cats, and the like. The compound of the inventionis also effective for obesity or obesity-related diseases in such dogs,cats, and the like. Whether treatment with the compound of the inventionis necessary can be readily determined by an ordinary physician,veterinarian, or clinician.

In clinical use of a compound according to the present invention forexample, the dose and dosing frequency vary depending on such factors asthe sex, age, and body weight of a patient, severity of symptoms, andthe type and range of intended effect. Generally, in oraladministration, the daily dose is preferably 0.01 to 100 mg/kg, morepreferably 0.03 to 1 mg/kg per adults, as a single dose or divideddoses. In the case of parenteral administration, the daily dose ispreferably 0.001 to 10 mg/kg, more preferably 0.001 to 0.1 mg/kg, evenmore preferably 0.01 to 0.1 mg/kg, given as a single dose or divideddoses.

A tablet for oral administration preferably contains 1.0 to 1,000 mg ofactive ingredient. Specifically, in order to allow for adjustment of thetherapeutic dose according to the symptoms of the patient to be treated,tablets containing 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0,150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, or1,000.0 mg of active ingredient are preferable. The compound may begiven 1 to 4 times a day, preferably 1 or 2 times a day.

In the case where the compound according to the invention is applied tothe treatment or prevention of obesity and/or diabetes and/orhyperlipidemia and/or dyslipidemia and/or non-alcoholic fatty liver orother diseases, when the daily dosage of the compound according to theinvention is about 0.1 mg to about 100 mg per kg of body weight ofanimal, more preferably, when the application is performed by a singleadministration or a divided administration of two to six times per day,or it is performed with a sustained-release preparation, a sufficientresult can be generally obtained. For most large mammals, the totaldaily dosage is from about 1.0 mg to about 1000 mg, preferably fromabout 1 mg to about 50 mg. In the case of an adult having a body weightof 70 kg, generally, the total daily dosage is presumably from about 7mg to about 350 mg. The prescription of this dosage can be adjusted forobtaining a maximum therapeutic effect.

Ordinary internists, veterinarians, or clinicians would be able toreadily decide and process the effective therapeutic dose of drugnecessary for the treatment, prevention, inhibition, suppression, orarrest of disease progression.

The preparation may contain 1.0 to 100 weight %, preferably 1.0 to 60weight % of a compound of the present invention with respect to thetotal of the drug. The preparation may further contain othertherapeutically effective compounds.

A compound according to the present invention can be used in combinationwith other agents useful for the care of diseases such as cardiovasculardisease, including hypertension, angina, heart failure, myocardialinfarction, stroke, claudication, diabetic nephropathy, diabeticretinopathy, failing vision, electrolyte abnormalities, andatherosclerosis; central neurologic disease, including, for example,bulimia, and diabetic neuropathy; metabolic disease, including, forexample, metabolic syndrome, obesity, diabetes mellitus, insulinresistance, hyperlipidemia, hypercholesteremia, neutral fathyperlipaemia, dyslipidemia, non-alcoholic fatty liver, abnormal hormonesecretion, gout, and fatty liver; reproductive disease, including, forexample, menstrual disturbance, and sexual dysfunction; digestivedisease, including liver dysfunction, pancreatitis, cholecystitis, andgastroesophageal reflux; respiratory disease, includingobesity-hypoventilation syndrome (Pickwickian syndrome), and sleepapnea; bacterial, fungal, or parasitic infectious disease; malignantneoplasm; and inflammatory disease, including arthritis, and skin ulcer.The individual components of such combinations may be administered as asingle or divided preparation, either simultaneously or at differenttimes during care. That is, the present invention should be construed asbeing inclusive of all administrations taking place simultaneously or atdifferent times, and “administration”, as that term is used herein,should be construed as such. In principle, a combination of a compoundof the present invention with other agents useful for the care ofvarious diseases includes combinations with any pharmaceuticalpreparations useful for the care of the diseases exemplified above.

The combination is inclusive of combinations containing a composition ofthe present invention and one or more other active substances. There aremany examples of a combination including a composition of the presentinvention and one or more active substances selected from thetherapeutic drugs for the diseases exemplified above. For example, forthe treatment, control, and prevention of metabolic syndrome, it isbeneficial to combine a composition of the present invention with one ormore active substances selected from a hyperlipidemia remedy, a lipidlowering drug, and an anti-diabetes mellitus drug. A compositionincluding an anti-obesity drug or anti-hypertension drug in addition tothe anti-diabetes mellitus drug and/or hyperlipidemia remedy or lipidlowering drug is particularly beneficial because it provides synergy inthe treatment, control, or prevention of metabolic syndrome.

Examples of the drugs that can be combined with a drug of the presentinvention include: ACAT inhibitor, a blocker, aldose reductaseinhibitor, a amylase inhibitor, angiotensin converting enzyme inhibitor,angiotensin receptor antagonist, anion-exchange resin, appetiteinhibitor, antioxidant, antiplatelet agent, β blocker, biguanide drug,calcium antagonist, CB1 receptor inverse agonist/antagonist, CETPinhibitor, cholesterol absorption inhibitor, DGAT inhibitor, DP-IVinhibitor, diuretic, eicosapentaenoic acid, endothelin antagonist, FLAPinhibitor, FXR modulator, ghrelin antagonist, GLP-1 agonist, GLP-1secreting agent, glucagon antagonist, glucokinase activator,glucocorticoid receptor ligand, α glycosidase inhibitor, GPAT inhibitor,histamine H3 receptor ligand, HMG-CoA reductase inhibitor, HSDinhibitor, insulin and its analogues, kinase inhibitor (such as VEGFinhibitor and PDGF inhibitor), leptin, lipase inhibitor, 5-LO inhibitor,LXR ligand, melanocortin agonist, MCH antagonist, MTTP inhibitor, orexinantagonist, opioid antagonist, neuropeptide Y antagonist, nicotinic acidagonist, PPAR ligand, PTP-1B inhibitor, SCD-1 inhibitor, serotonintransporter inhibitor, SGLT inhibitor, SUR ligand, thyroid hormoneagonist, UCP activator, and VPAC receptor agonist.

ADVANTAGE OF THE INVENTION

A compound according to the present invention has an excellent LCEinhibiting effect, and is therefore useful as a remedy for a variety ofdiseases involving LCE, for example, such as cardiovascular disease,neurologic disease, metabolic disease, reproductive disease, digestivedisease, neoplasm, and infection. A compound according to the presentinvention is also useful as a herbicide.

BEST MODE FOR CARRYING OUT THE INVENTION

The present invention is described below in more detail based onproduction examples and examples. It should be noted, however, that theinvention is in no way limited by the following descriptions.

EXAMPLES

In thin-layer chromatography, a Silica gel₆₀F₂₅₄ (Merck) was used as theplate, and the detection was made using a UV detector. As the columnsilica gel, Wakogel™ C-300 or C-200 (Wako Pure Chemical Industries,Ltd.), and FLASH+cartridge (Biotage) or Chromatorex (Fuji SilysiaChemical) were used. MS spectra were measured using ZQ 2000 (Waters). Inthe measurement of NMR spectra, dimethyl sulfoxide was used as theinternal reference when using a deuterated dimethyl sulfoxide solution,and measurements were made using a JNM-AL 400 (JEOL), Mercury 400 (400MHz; Varian), or Inova 400 (400 MHz; Varian) spectrometer. All 6 valuesare given in ppm.

The meaning of the abbreviations used in the NMR measurement is asfollows.

s: Singlet

d: Doublet

dd: Double doublet

t: Triplet

dt: Double triplet

q: Quartet

m: Multiplet

br: Broad

J: Coupling constant

Hz: Hertz

DMSO-d₆: Deuterated dimethyl sulfoxide

In the following, (1R*,4S*,6R*) means a 1:1 mixture of (1R,4S,6R) and(1S,4R,6S), and (1R*,2R*,5R*) means a 1:1 mixture of (1R,2R,5R) and(1S,2S,5S). (1R**,4S**,6R**) or (1S**,4R**,6S**) means one of theenantiomers (1R,4S,6R) and (1S,4R,6S).

Reference Example 1 Synthesis of 1-(Butylsulfonyl)-N-(4-isopropoxyphenyl)piperidine-3-carboxamide (1) Synthesisof 1-(Butylsulfonyl)piperidine-3-carboxylic Acid

1N-sodium hydroxide aqueous solution (4.1 mL) was added to nipecoticacid (500 mg, 3.87 mmol), and, under ice-cooling, butanesulfonylchloride(0.98 mL, 7.74 mmol) was added dropwise. The mixture was raised to roomtemperature, and stirred for 15 hours. The reaction mixture was thenextracted with chloroform. The organic layer was collected, dried overmagnesium sulfate, and concentrated under reduced pressure. Theresulting residue was then purified using silica gel columnchromatography to obtain the target (354 mg, 37%).

(2) Synthesis of Title compound

1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (57.5 mg,0.3 mmol) was added to a pyridine (5 mL) solution of the compound (50mg, 0.2 mmol) synthesized in (1) and 4-isopropoxyaniline (0.061 mg, 0.4mmol), and the mixture was stirred at room temperature for 3 hours. Thereaction mixture was concentrated under reduced pressure, and, afteraddition of ethyl acetate, washed once with 1N-sodium hydroxidesolution, and once with saturated brine. The organic layer was driedover magnesium sulfate, and concentrated under reduced pressure. Theresulting residue was then purified using silica gel columnchromatography to obtain the title compound (33 mg, 43%).

1H-NMR (400 MHz, CDCl₃, δ): 0.95 (3H, t, J=7.3 Hz), 1.31 (6H, d, J=5.9Hz), 1.40-1.51 (2H, m), 1.65-2.02 (6H, m), 2.54-2.63 (1H, m), 2.90-2.98(2H, m), 2.99-3.08 (1H, m), 3.21-3.33 (1H, m), 3.53-3.64 (1H, m),3.72-3.79 (1H, m), 4.44-4.54 (1H, m), 6.81-6.87 (2H, m), 7.39-7.45 (2H,m), 7.63 (1H, br s).

ESI-MS (m/e): 383.1 [M+H]⁺

Reference Example 2 Synthesis ofN-(4-Isopropoxyphenyl)-1-(phenylsulfonyl)piperidine-3-carboxamide

The title compound was synthesized as in Reference Example 1, usingbenzenesulfonyl chloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, d, J=5.9 Hz), 1.68-1.91 (4H, m),2.58-2.71 (2H, m), 2.83-2.93 (1H, m), 3.41-3.51 (1H, m), 3.56-3.66 (1H,m), 4.45-4.55 (1H, m), 6.82-6.87 (2H, m), 7.41-7.46 (2H, m), 7.53-7.58(2H, m), 7.60-7.65 (1H, m), 7.69 (1H, br s), 7.75-7.80 (2H, m).

ESI-MS (m/e): 403.2 [M+H]⁺

Reference Example 3 Synthesis of2-Methoxy-N-{[1-(phenylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 7 and benzenesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.11-1.23 (1H, m), 1.58-1.69 (1H, m),1.70-1.84 (2H, m), 1.96-2.10 (1H, m), 2.45-2.53 (1H, m), 2.59-2.67 (1H,m), 3.31-3.43 (2H, m), 3.46-3.54 (2H, m), 4.02 (3H, s), 6.97-7.03 (1H,m), 7.05-7.12 (1H, m), 7.42-7.63 (4H, m), 7.72-7.77 (2H, m), 7.96-8.05(1H, m), 8.16-8.22 (1H, m).

ESI-MS (m/e): 389.0 [M+H]⁺

Example 1 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-isopropoxyaniline asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.31 (6H, d, J=6.3Hz), 1.40-1.53 (2H, m), 1.58-1.88 (6H, m), 1.93-2.04 (1H, m), 2.07-2.16(1H, m), 2.27-2.39 (1H, m), 2.89-3.13 (3H, m), 3.22-3.31 (1H, m),3.51-3.62 (1H, m), 3.92-3.99 (1H, m), 4.44-4.56 (1H, m), 6.81-6.87 (2H,m), 7.36-7.43 (2H, m), 7.48 (1H, br s).

ESI-MS (m/e): 409.2 [M+H]⁺

Example 2 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-phenyl-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and aniline as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 0.88-1.01 (3H, m), 1.40-1.52 (2H, m),1.55-1.66 (1H, m), 1.74-1.89 (4H, m), 1.93-2.15 (3H, m), 2.28-2.37 (1H,m), 2.90-3.17 (3H, m), 3.22-3.30 (1H, m), 3.53-3.61 (1H, m), 3.94-4.01(1H, m), 7.06-7.14 (1H, m), 7.28-7.36 (2H, m), 7.51-7.57 (2H, m), 7.82(1H, br s).

ESI-MS (m/e): 351.2 [M+H]⁺

Example 3 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(4-methoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-methoxyaniline as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.38-1.52 (2H, m),1.56-1.67 (1H, m), 1.72-2.03 (6H, m), 2.07-2.16 (1H, m), 2.27-2.36 (1H,m), 2.92-3.13 (3H, m), 3.23-3.31 (1H, m), 3.51-3.59 (1H, m), 3.79 (3H,s), 3.93-3.98 (1H, m), 6.81-6.89 (2H, m), 7.39-7.47 (2H, m), 7.66 (1H,br s).

ESI-MS (m/e): 381.1 [M+H]⁺

Example 4 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(4-fluorophenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-fluoroaniline as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.38-1.52 (2H, m),1.55-1.68 (1H, m), 1.73-1.90 (4H, m), 1.92-2.15 (3H, m), 2.27-2.37 (1H,m), 2.87-3.16 (3H, m), 3.21-3.30 (1H, m), 3.50-3.59 (1H, m), 3.89-4.00(1H, m), 6.95-7.06 (2H, m), 7.45-7.54 (2H, m), 7.89 (1H, br s).

ESI-MS (m/e): 369.1 [M+H]⁺

Example 5 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-[4-(trifluoromethyl)phenyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-trifluoromethylanilineas the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.40-1.52 (2H, m),1.58-2.00 (7H, m), 2.11-2.17 (1H, m), 2.27-2.37 (1H, m), 2.92-3.08 (2H,m), 3.11-3.18 (1H, m), 3.22-3.30 (1H, m), 3.55-3.64 (1H, m), 3.94-4.00(1H, m), 7.53-7.61 (2H, m), 7.65-7.73 (2H, m), 8.09 (1H, br s).

ESI-MS (m/e): 419.2 [M+H]⁺

Example 6 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(4-methylphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-methylaniline as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.41-1.53 (2H, m),1.75-1.88 (6H, m), 1.92-2.02 (1H, m), 2.09-2.15 (1H, m), 2.28-2.36 (4H,m), 2.91-3.12 (3H, m), 3.24-3.29 (1H, m), 3.54-3.60 (1H, m), 3.93-3.97(1H, m), 7.09-7.15 (2H, m), 7.38-7.43 (2H, m), 7.54 (1H, br s).

ESI-MS (m/e): 365.3 [M+H]⁺

Example 7 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(4-isopropylphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-isopropylaniline as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.23 (6H, d, J=6.8Hz), 1.40-1.52 (2H, m), 1.75-1.89 (5H, m), 1.93-2.02 (1H, m), 2.08-2.15(1H, m), 2.25-2.40 (1H, m), 2.77-3.13 (4H, m), 3.22-3.32 (1H, m),3.52-3.61 (1H, m), 3.91-3.99 (1H, m), 7.13-7.20 (2H, m), 7.40-7.48 (2H,m), 7.56 (1H, br s).

ESI-MS (m/e): 393.3 [M+H]⁺

Example 8 Synthesis of (1R*,4S*,6R*)-N-[4-(Benzyloxy)phenyl]-2-(butylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-benzyloxyaniline as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.41-1.50 (2H, m),1.74-1.88 (6H, m), 1.93-2.01 (1H, m), 2.08-2.15 (1H, m), 2.26-2.37 (1H,m), 2.91-3.04 (2H, m), 3.05-3.11 (1H, m), 3.24-3.30 (1H, m), 3.54-3.60(1H, m), 3.93-3.97 (1H, m), 5.05 (2H, s), 6.90-6.95 (2H, m), 7.30-7.46(7H, m), 7.54 (1H, br s).

ESI-MS (m/e): 457.2 [M+H]⁺

Example 9 Synthesis of (1R*,4S*,6R*)-N-(4-Benzylphenyl)-2-(butylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-benzylaniline as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.2 Hz), 1.40-1.50 (2H, m),1.55-2.02 (8H, m), 2.09-2.14 (1H, m), 2.26-2.35 (1H, m), 2.90-3.13 (3H,m), 3.23-3.30 (1H, m), 3.54-3.61 (1H, m), 3.94 (2H, s), 7.10-7.22 (6H,m), 7.41-7.48 (2H, m), 7.63 (1H, br s).

ESI-MS (m/e): 441.2 [M+H]⁺

Example 10 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(4-phenoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-phenoxyaniline as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.97 (3H, t, J=7.4 Hz), 1.21-1.29 (1H, m),1.40-1.51 (2H, m), 1.59-1.89 (5H, m), 1.92-2.04 (1H, m), 2.09-2.16 (1H,m), 2.25-2.38 (1H, m), 2.90-3.15 (3H, m), 3.22-3.32 (1H, m), 3.55-3.61(1H, m), 3.94-3.99 (1H, m), 6.94-7.02 (4H, m), 7.05-7.11 (1H, m),7.30-7.35 (2H, m), 7.47-7.54 (2H, m), 7.72 (1H, br s).

ESI-MS (m/e): 443.2 [M+H]⁺

Example 11 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-[4-(trifluoromethoxy)phenyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 4-trifluoromethoxyanilineas the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.38-1.52 (2H, m),1.57-1.69 (1H, m), 1.73-1.88 (5H, m), 1.91-1.99 (1H, m), 2.09-2.17 (1H,m), 2.28-2.37 (1H, m), 2.90-3.15 (3H, m), 3.23-3.31 (1H, m), 3.56-3.61(1H, m), 3.93-3.97 (1H, m), 7.14-7.20 (2H, m), 7.55-7.61 (2H, m), 7.95(1H, br s).

ESI-MS (m/e): 435.2 [M+H]⁺

Example 12 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(2-methoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 2-methoxyaniline as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.97 (3H, t, J=7.3 Hz), 1.42-1.51 (2H, m),1.55-1.65 (1H, m), 1.75-1.91 (5H, m), 1.97-2.07 (1H, m), 2.09-2.15 (1H,m), 2.21-2.34 (1H, m), 2.87-3.05 (2H, m), 3.11-3.20 (1H, m), 3.26-3.35(1H, m), 3.51-3.59 (1H, m), 3.89 (3H, s), 3.97-4.05 (1H, m), 6.86-6.90(1H, m), 6.92-6.98 (1H, m), 7.02-7.10 (1H, m), 7.86 (1H, br s),8.26-8.35 (1H, m).

ESI-MS (m/e): 381.2 [M+H]⁺

Example 13 Synthesis of(1R*,4S*,6R*)-2-[(2,5-Difluorophenyl)sulfonyl]-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

Triethylamine (0.051 mL, 0.368 mmol) and 2,5-difluorobenzenesulfonylchloride (0.0162 mL, 0.12 mmol) were added to a chloroform (1 mL)solution of the title compound (30 mg, 0.092 mmol) of Production Example2, and the mixture was stirred at room temperature for 19 hours. Thereaction mixture was then washed once with a saturated sodium hydrogencarbonate aqueous solution, dried over magnesium sulfate, andconcentrated under reduced pressure. The resulting residue was thenpurified using silica gel column chromatography to obtain the titlecompound (27 mg, 63%).

1H-NMR (400 MHz, CDCl₃, δ): 1.32 (6H, d, J=5.9 Hz), 1.46-1.56 (1H, m),1.61-1.70 (1H, m), 1.73-1.91 (3H, m), 2.09-2.14 (1H, m), 2.26-2.35 (1H,m), 2.95-3.02 (1H, m), 3.36-3.42 (1H, m), 3.44-3.50 (1H, m), 4.12-4.17(1H, m), 4.45-4.55 (1H, m), 6.81-6.88 (2H, m), 7.18-7.31 (2H, m),7.36-7.43 (3H, m), 7.61-7.67 (1H, m).

ESI-MS (m/e): 465.2 [M+H]⁺

Example 14 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-(methylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and methanesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, d, J=5.9 Hz), 1.55-1.66 (1H, m),1.77-1.90 (3H, m), 1.93-2.03 (1H, m), 2.10-2.16 (1H, m), 2.29-2.38 (1H,m), 2.91 (3H, s), 3.02-3.10 (1H, m), 3.27-3.32 (1H, m), 3.48-3.54 (1H,m), 3.99-4.03 (1H, m), 4.44-4.54 (1H, m), 6.81-6.87 (2H, m), 7.37-7.43(2H, m), 7.55 (1H, br s).

ESI-MS (m/e): 367.2 [M+H]⁺

Example 15 Synthesis of(1R*,4S*,6R*)-2-(Ethylsulfonyl)-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and ethanesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, d, J=5.9 Hz), 1.37 (3H, t, J=7.3Hz), 1.55-1.66 (1H, m), 1.75-1.89 (3H, m), 1.94-2.05 (1H, m), 2.08-2.14(1H, m), 2.27-2.36 (1H, m), 2.94-3.11 (3H, m), 3.24-3.30 (1H, m),3.54-3.60 (1H, m), 3.92-3.97 (1H, m), 4.44-4.55 (1H, m), 6.80-6.88 (2H,m), 7.38-7.45 (2H, m), 7.56 (1H, br s).

ESI-MS (m/e): 381.2 [M+H]⁺

Example 16 Synthesis of(1R*,4S*,6R*)-N-(4-isopropoxyphenyl)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and benzenesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.28-1.38 (7H, m), 1.42-1.52 (1H, m),1.62-1.82 (3H, m), 2.02-2.08 (1H, m), 2.17-2.27 (1H, m), 2.82-2.91 (1H,m), 3.23-3.28 (1H, m), 3.44-3.50 (1H, m), 4.03-4.08 (1H, m), 4.46-4.53(1H, m), 6.82-6.88 (2H, m), 7.34-7.42 (3H, m), 7.52-7.57 (2H, m),7.59-7.64 (1H, m), 7.86-7.92 (2H, m).

ESI-MS (m/e): 429.2 [M+H]⁺

Example 17 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-[(4-methoxyphenyl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 4-methoxybenzenesulfonyl chlorideas the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.25-1.40 (7H, m), 1.43-1.53 (1H, m),1.63-1.82 (3H, m), 1.99-2.06 (1H, m), 2.17-2.27 (1H, m), 2.84-2.93 (1H,m), 3.17-3.27 (1H, m), 3.39-3.47 (1H, m), 3.88 (3H, s), 3.99-4.05 (1H,m), 4.44-4.55 (OH, m), 6.81-6.88 (2H, m), 6.97-7.03 (2H, m), 7.36-7.42(3H, m), 7.76-7.85 (2H, m).

ESI-MS (m/e): 459.2 [M+H]⁺

Example 18 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 4-trifluoromethylbenzenesulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.24-1.37 (7H, m), 1.38-1.49 (1H, m),1.63-1.88 (3H, m), 2.04-2.11 (1H, m), 2.20-2.29 (1H, m), 2.93-3.01 (1H,m), 3.19-3.24 (1H, m), 3.49-3.55 (1H, m), 4.08-4.16 (1H, m), 4.45-4.56(1H, m), 6.82-6.90 (2H, m), 7.35-7.44 (3H, m), 7.76-7.84 (2H, m),7.96-8.03 (2H, m).

ESI-MS (m/e): 497.2 [M+H]⁺

Example 19 Synthesis of (1R*,4S*,6R*)-2-[(4-tert-Butylphenyl)sulfonyl]-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 4-tert-butylbenzenesulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, d, J=5.9 Hz), 1.34 (9H, s),1.44-1.55 (1H, m), 1.62-1.83 (3H, m), 1.94-2.05 (2H, m), 2.17-2.27 (1H,m), 2.86-2.94 (1H, m), 3.22-3.28 (1H, m), 3.42-3.48 (1H, m), 4.05-4.09(1H, m), 4.44-4.54 (1H, m), 6.78-6.86 (2H, m), 7.36-7.42 (2H, m),7.51-7.56 (3H, m), 7.76-7.83 (2H, m).

ESI-MS (m/e): 485.2 [M+H]⁺

Example 20 Synthesis of(1R*,4S*,6R*)-2-[(3-Fluorophenyl)sulfonyl]-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 3-fluorobenzenesulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.26-1.39 (7H, m), 1.41-1.52 (1H, m),1.63-1.85 (3H, m), 2.03-2.10 (1H, m), 2.20-2.29 (1H, m), 2.87-2.97 (1H,m), 3.21-3.28 (1H, m), 3.45-3.53 (1H, m), 4.04-4.10 (1H, m), 4.45-4.55(1H, m), 6.82-6.89 (2H, m), 7.28-7.34 (1H, m), 7.36-7.43 (3H, m),7.50-7.60 (2H, m), 7.64-7.70 (1H, m).

ESI-MS (m/e): 447.1 [M+H]⁺

Example 21 Synthesis of(1R*,4S*,6R*)-2-[(4-Fluorophenyl)sulfonyl]-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 4-fluorobenzenesulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.23-1.38 (7H, m), 1.39-1.49 (1H, m),1.63-1.85 (3H, m), 2.02-2.09 (1H, m), 2.19-2.28 (1H, m), 2.90-2.99 (1H,m), 3.17-3.24 (1H, m), 3.44-3.51 (1H, m), 4.03-4.10 (1H, m), 4.44-4.57(1H, m), 6.82-6.88 (2H, m), 7.18-7.24 (2H, m), 7.37-7.45 (3H, m),7.85-7.92 (2H, m).

ESI-MS (m/e): 447.1 [M+H]⁺

Example 22 Synthesis of(1R*,4S*,6R*)-2-[(2-Fluorophenyl)sulfonyl]-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 2-fluorobenzenesulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.32 (6H, d, J=6.3 Hz), 1.46-1.56 (1H, m),1.62-1.88 (4H, m), 2.05-2.12 (1H, m), 2.24-2.34 (1H, m), 2.92-3.01 (1H,m), 3.36-3.47 (2H, m), 4.12-4.16 (1H, m), 4.44-4.55 (1H, m), 6.80-6.90(2H, m), 7.21-7.32 (2H, m), 7.36-7.44 (3H, m), 7.53-7.62 (1H, m),7.89-7.97 (1H, m).

ESI-MS (m/e): 447.1 [M+H]⁺

Example 23 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-[(3-methoxyphenyl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 3-methoxybenzenesulfonyl chlorideas the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.26-1.43 (7H, m), 1.46-1.60 (1H, m),1.65-1.84 (3H, m), 2.01-2.08 (1H, m), 2.17-2.26 (1H, m), 2.75-2.83 (1H,m), 3.26-3.33 (1H, m), 3.41-3.48 (1H, m), 3.87 (3H, s), 4.02-4.07 (1H,m), 4.44-4.55 (1H, m), 6.82-6.88 (2H, m), 7.11-7.17 (1H, m), 7.30-7.34(1H, m), 7.37-7.42 (3H, m), 7.44-7.49 (2H, m).

ESI-MS (m/e): 459.2 [M+H]⁺

Example 24 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-(pyridin-3-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 3-pyridinesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.26-1.39 (7H, m), 1.41-1.51 (1H, m),1.66-1.90 (3H, m), 2.04-2.11 (1H, m), 2.21-2.28 (1H, m), 2.89-2.97 (1H,m), 3.20-3.27 (1H, m), 3.47-3.52 (1H, m), 4.09-4.16 (1H, m), 4.44-4.55(1H, m), 6.80-6.88 (2H, m), 7.37-7.43 (2H, m), 7.45-7.53 (2H, m),8.12-8.18 (1H, m), 8.80-8.87 (1H, m), 9.07-9.12 (1H, m).

ESI-MS (m/e): 430.1 [M+H]⁺

Example 25 Synthesis of(1R*,4S*,6R*)-2-[(2,5-Dichloro-3-thienyl)sulfonyl]-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 2,5-dichlorothiophene-3-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.32 (6H, d, J=6.3 Hz), 1.49-1.85 (3H, m),1.87-1.97 (1H, m), 2.09-2.14 (1H, m), 2.23-2.32 (1H, m), 2.91-3.01 (1H,m), 3.36-3.42 (1H, m), 3.48-3.54 (1H, m), 4.06-4.11 (1H, m), 4.45-4.55(1H, m), 6.82-6.89 (2H, m), 7.13 (1H, s), 7.36-7.42 (2H, m).

ESI-MS (m/e): 503.2 [M+H]⁺

Example 26 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 1-methylimidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.32 (6H, d, J=6.3 Hz), 1.41-1.52 (1H, m),1.56-1.66 (1H, m), 1.70-1.98 (3H, m), 2.00-2.05 (1H, m), 2.15-2.24 (1H,m), 2.94-3.02 (2H, m), 3.43-3.48 (1H, m), 3.80 (3H, s), 4.28-4.31 (1H,m), 4.46-4.54 (1H, m), 6.82-6.88 (2H, m), 7.46-7.52 (3H, m), 7.59-7.63(1H, m), 8.62 (1H, br s).

ESI-MS (m/e): 433.3 [M+H]⁺

Example 27 Synthesis of(1R*,4S*,6R*)-2-[(1,2-Dimethyl-1H-imidazol-4-yl)sulfonyl]-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 1,2-dimethylimidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.32 (6H, d, J=6.3 Hz), 1.41-1.51 (1H, m),1.57-1.67 (1H, m), 1.70-1.98 (3H, m), 2.00-2.05 (1H, m), 2.16-2.24 (1H,m), 2.41 (3H, s), 2.92-3.03 (2H, m), 3.40-3.47 (1H, m), 3.66 (3H, s),4.26-4.31 (1H, m), 4.45-4.55 (1H, m), 6.82-6.88 (2H, m), 7.41 (1H, s),7.48-7.54 (2H, m), 8.83 (1H, br s).

ESI-MS (m/e): 447.3 [M+H]⁺

Example 28 Synthesis of(1R*,4S*,6R*)-2-{[2-(Acetylamino)-4-methyl-1,3-thiazol-5-yl]sulfonyl}-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and2-acetamide-4-methyl-5-thiazolesulfonyl chloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.32 (6H, d, J=5.9 Hz), 1.46-1.57 (1H, m),1.64-1.95 (4H, m), 2.06-2.14 (1H, m), 2.21-2.31 (4H, m), 2.58 (3H, s),2.89-2.97 (1H, m), 3.35-3.46 (2H, m), 4.04-4.10 (1H, m), 4.45-4.55 (1H,m), 6.82-6.87 (2H, m), 7.35 (1H, br s), 7.39-7.45 (2H, m).

ESI-MS (m/e): 507.3 [M+H]⁺

Example 29 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-(2-thienylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and thiophene-2-sulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.32 (6H, d, J=6.3 Hz), 1.39-1.47 (1H, m),1.51-1.84 (4H, m), 2.05-2.11 (1H, m), 2.19-2.27 (1H, m), 2.75-2.83 (1H,m), 3.34-3.48 (2H, m), 4.04-4.09 (1H, m), 4.45-4.56 (1H, m), 6.82-6.88(2H, m), 7.13-7.16 (1H, m), 7.20 (1H, br s), 7.35-7.42 (2H, m),7.59-7.65 (2H, m).

ESI-MS (m/e): 435.3 [M+H]⁺

Example 30 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-(3-thienylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

Triethylamine (0.065 mL, 0.42 mmol) and 20% palladium hydroxide-carboncatalyst (8 mg) were added to a methanol (2 mL) solution of the compound(35 mg, 0.0695 mmol) synthesized in Example 25, and the mixture wasstirred for 5 hours in a hydrogen (4 atm) atmosphere. The reactionmixture was then celite filtered, and the filtrate was concentrated. Theresulting residue was then purified using silica gel columnchromatography to obtain the target (9.9 mg, 33%).

1H-NMR (400 MHz, CDCl₃, δ): 1.25-1.42 (7H, m), 1.46-1.58 (1H, m),1.66-1.85 (3H, m), 2.04-2.10 (1H, m), 2.19-2.27 (1H, m), 2.83-2.91 (1H,m), 3.25-3.32 (1H, m), 3.42-3.49 (1H, m), 4.04-4.09 (1H, m), 4.44-4.55(1H, m), 6.82-6.88 (2H, m), 7.29 (1H, br s), 7.35-7.43 (3H, m),7.44-7.48 (1H, m), 7.96-7.99 (1H, m)

ESI-MS (m/e): 435.1 [M+H]⁺

Example 31 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-(propylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and 1-propanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.07 (3H, t, J=7.4 Hz), 1.31 (6H, d, J=6.1Hz), 1.52-1.66 (1H, m), 1.75-1.91 (5H, m), 1.94-2.04 (1H, m), 2.08-2.14(1H, m), 2.27-2.36 (1H, m), 2.88-3.02 (2H, m), 3.04-3.11 (1H, m),3.24-3.30 (1H, m), 3.53-3.60 (1H, m), 3.92-3.98 (1H, m), 4.45-4.55 (1H,m), 6.80-6.87 (2H, m), 7.37-7.43 (2H, m), 7.53 (1H, br s).

ESI-MS (m/e): 395.1 [M+H]⁺

Example 32 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-(isopropylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and isopropylsulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, d, J=6.1 Hz), 1.35-1.41 (6H, m),1.57-1.66 (1H, m), 1.77-1.91 (3H, m), 1.94-2.04 (1H, m), 2.07-2.13 (1H,m), 2.25-2.35 (1H, m), 3.05-3.12 (1H, m), 3.14-3.22 (1H, m), 3.23-3.29(1H, m), 3.64-3.71 (1H, m), 3.86-3.92 (1H, m), 4.45-4.53 (1H, m),6.80-6.87 (2H, m), 7.37-7.46 (3H, m).

ESI-MS (m/e): 395.2 [M+H]⁺

Example 33 Synthesis of(1R*,4S*,6R*)-2-(Cyclopropylsulfonyl)-N-(4-isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and cyclopropylsulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.92-1.07 (2H, m), 1.12-1.27 (2H, m),1.56-1.68 (1H, m), 1.76-2.01 (4H, m), 2.06-2.14 (1H, m), 2.27-2.44 (2H,m), 3.05-3.13 (1H, m), 3.35-3.42 (1H, m), 3.48-3.54 (1H, m), 3.94-4.01(1H, m), 4.43-4.56 (1H, m), 6.79-6.88 (2H, m), 7.38-7.45 (2H, m), 7.57(1H, br s).

ESI-MS (m/e): 393.2 [M+H]⁺

Example 34 Optical resolution of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The compound (60 mg, 0.138 mmol) synthesized in Example 26 was opticallyresolved using normal-phase chiral HPLC(CHIRALPAK AD 2 cm ø×25 cmL(Daicel Chemical Industries, Ltd.); mobile phase: hexane:isopropylalcohol=60:40; flow rate: 10 ml/min; isogradient), and(1R**,4S**,6R**)-N-(4-isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide(retention time: 14.2 min; 26.6 mg), and(1S**,4R**,6S**)-N-(4-isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide(retention time: 30.7 min; 29.4 mg) were obtained.

Example 35 Synthesis of (1R*,2R*,5R*)-8-(Butylsulfonyl)-N-(4-isopropoxyphenyl)-8-azabicyclo[3.2.1]octane-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 3 and 1-butanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.96 (3H, t, J=7.3 Hz), 1.31 (6H, d, J=6.1Hz), 1.40-1.52 (2H, m), 1.60-1.70 (1H, m), 1.72-1.85 (5H, m), 1.87-2.14(4H, m), 2.20-2.31 (1H, m), 2.77-2.87 (1H, m), 2.93-3.01 (2H, m),4.13-4.20 (1H, m), 4.31-4.39 (1H, m), 4.45-4.55 (1H, m), 6.80-6.88 (2H,m), 7.35-7.43 (3H, m).

ESI-MS (m/e): 409.1 [M+H]⁺

Example 36 Synthesis of(1R*,2R*,5R*)-N-(4-Isopropoxyphenyl)-8-(phenylsulfonyl)-8-azabicyclo[3.2.1]octane-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 3 and benzenesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.23-1.55 (8H, m), 1.58-1.68 (1H, m),1.73-2.09 (5H, m), 2.81-2.90 (1H, m), 4.21-4.29 (1H, m), 4.38-4.44 (1H,m), 4.46-4.54 (1H, m), 6.78-6.87 (2H, m), 7.37-7.45 (2H, m), 7.46-7.53(2H, m), 7.56-7.62 (2H, m), 7.84-7.91 (2H, m).

ESI-MS (m/e): 429.1 [M+H]⁺

Example 37 Synthesis of(1R*,2R*,5R*)-N-(4-Isopropoxyphenyl)-8-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-8-azabicyclo[3.2.1]octane-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 3 and 1-methylimidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, d, J=6.1 Hz), 1.50-1.64 (2H, m),1.69-1.89 (3H, m), 1.94-2.12 (2H, m), 2.23-2.37 (1H, m), 2.84-2.97 (1H,m), 3.75 (3H, s), 4.26-4.35 (1H, m), 4.41-4.54 (2H, m), 6.78-6.86 (2H,m), 7.38-7.46 (3H, m), 7.50 (1H, s), 7.87 (1H, s).

ESI-MS (m/e): 433.1 [M+H]⁺

Example 38 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-(pyridin-2-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and pyridine-2-sulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.32 (6H, d, J=5.9 Hz), 1.47-1.64 (2H, m),1.69-1.85 (3H, m), 2.01-2.08 (1H, m), 2.24-2.33 (1H, m), 3.03-3.12 (1H,m), 3.25-3.32 (1H, m), 3.46-3.53 (1H, m), 4.28-4.32 (1H, m), 4.46-4.54(1H, m), 6.82-6.89 (2H, m), 7.38-7.47 (2H, m), 7.52-7.57 (1H, m), 7.73(1H, br s), 7.91-7.99 (1H, m), 8.02-8.07 (1H, m), 8.70-8.78 (1H, m).

ESI-MS (m/e): 430.0 [M+H]⁺

Example 39 Synthesis of(1R*,2R*,5R*)-N-(4-Isopropoxyphenyl)-8-(pyridin-2-ylsulfonyl)-8-azabicyclo[3.2.1]octane-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 3 and pyridine-2-sulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, dd, J=5.9, 2.4 Hz), 1.43-1.81 (5H,m), 1.85-1.96 (1H, m), 1.99-2.13 (2H, m), 2.82-2.98 (1H, m), 4.34-4.39(1H, m), 4.44-4.57 (2H, m), 6.80-6.89 (2H, m), 7.36-7.42 (2H, m),7.46-7.54 (2H, m), 7.86-7.94 (1H, m), 7.98-8.04 (1H, m), 8.66-8.74 (1H,m).

ESI-MS (m/e): 430.2 [M+H]⁺

Example 40 Synthesis of(1R*,2R*,5R*)-N-(4-Isopropoxyphenyl)-8-(pyridin-3-ylsulfonyl)-8-azabicyclo[3.2.1]octane-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 3 and pyridine-3-sulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, d, J=5.9 Hz), 1.34-1.54 (1H, m),1.56-1.69 (2H, m), 1.75-1.84 (1H, m), 1.88-2.06 (3H, m), 2.10-2.18 (1H,m), 2.81-2.87 (1H, m), 4.23-4.30 (1H, m), 4.40-4.56 (2H, m), 6.79-6.88(2H, m), 7.36-7.56 (4H, m), 8.12-8.20 (1H, m), 8.79-8.85 (1H, m),9.07-9.12 (1H, m).

ESI-MS (m/e): 430.2 [M+H]⁺

Example 41 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(3-methoxypyridin-2-yl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and 2-amino-3-methoxypyridineas the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.97 (3H, t, J=7.3 Hz), 1.41-1.53 (2H, m),1.58-1.68 (1H, m), 1.75-1.90 (6H, m), 1.95-2.07 (1H, m), 2.08-2.14 (1H,m), 2.33-2.42 (1H, m), 2.96-3.12 (2H, m), 3.34-3.41 (1H, m), 3.44-3.51(1H, m), 3.89 (3H, s), 4.07-4.16 (1H, m), 6.97-7.07 (1H, m), 7.10-7.16(1H, m), 7.92-8.09 (2H, m).

ESI-MS (m/e): 382.4 [M+H]⁺

Example 42 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 1 and5-cyclopropyl-1H-pyrazole-3-amine as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.76-0.83 (2H, m), 0.93-1.01 (5H, m),1.42-1.53 (2H, m), 1.57-1.66 (1H, m), 1.69-1.99 (6H, m), 2.03-2.14 (2H,m), 2.26-2.36 (1H, m), 2.90-3.11 (3H, m), 3.23-3.29 (1H, m), 3.53-3.59(1H, m), 4.02-4.06 (1H, m), 6.37 (1H, s), 11.46 (1H, br s).

ESI-MS (m/e): 381.4 [M+H]⁺

Example 43 Synthesis of(1R*,4S*,6R*)-N-(3-methoxypyridin-2-yl)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 19 and benzenesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.19-1.43 (1H, m), 1.48-1.61 (1H, m),1.66-1.94 (4H, m), 2.00-2.10 (1H, m), 2.16-2.27 (1H, m), 3.27-3.44 (2H,m), 3.92 (3H, s), 4.20-4.28 (1H, m), 6.99-7.07 (1H, m), 7.13-7.19 (1H,m), 7.47-7.63 (3H, m), 7.85-7.96 (3H, m), 8.01-8.05 (1H, m).

ESI-MS (m/e): 402.2 [M+H]⁺

Example 44 Synthesis of(1R*,4S*,6R*)-N-(5-Isopropoxypyridin-2-yl)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

Diisopropylethylamine (0.071 mL, 0.41 mmol) and HATU (42.7 mg, 0.11mmol) were added to a DMF (1 mL) solution of the title compound (30 mg,0.11 mmol) of Production Example 4 and the title compound (21.1 mg, 0.11mmol) of Production Example 20, and the mixture was stirred at roomtemperature for 14 hours. The reaction mixture was diluted with ethylacetate, and washed twice with a saturated sodium hydrogen carbonateaqueous solution. The organic layer was dried over magnesium sulfate,and concentrated under reduced pressure. The resulting residue was thenpurified using silica gel column chromatography to obtain the titlecompound (18.7 mg, 43%).

1H-NMR (400 MHz, CDCl₃, δ): 1.31-1.44 (7H, m), 1.49-1.60 (1H, m),1.62-1.80 (3H, m), 2.01-2.09 (1H, m), 2.13-2.23 (1H, m), 2.77-2.85 (1H,m), 3.29-3.35 (1H, m), 3.38-3.45 (1H, m), 4.05-4.17 (1H, m), 4.47-4.57(1H, m), 7.20-7.25 (1H, m), 7.53-7.64 (3H, m), 7.86-7.98 (3H, m),8.00-8.10 (2H, m).

ESI-MS (m/e): 430.2 [M+H]⁺

Example 45 Synthesis of(1R*,4S*,6R*)-N-(3-Isopropoxyphenyl)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 44, using the titlecompound of Production Example 4 and 3-isopropoxyaniline as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.33 (6H, d, J=6.1 Hz), 1.41-1.50 (1H, m),1.63-1.96 (4H, m), 2.02-2.09 (1H, m), 2.17-2.28 (1H, m), 2.86-2.95 (1H,m), 3.22-3.29 (1H, m), 3.44-3.52 (1H, m), 4.02-4.09 (1H, m), 4.51-4.60(1H, m), 6.60-6.68 (1H, m), 6.92-7.01 (1H, m), 7.15-7.22 (1H, m),7.50-7.67 (4H, m), 7.83-7.93 (2H, m).

ESI-MS (m/e): 429.2 [M+H]⁺

Example 46 Synthesis of(1R*,4S*,6R*)-N-(3-Methoxypyridin-2-yl)-2-(pyridin-2-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 19 and pyridine-2-sulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.44-1.55 (1H, m), 1.63-1.82 (4H, m),1.86-1.95 (1H, m), 2.01-2.08 (1H, m), 2.24-2.36 (1H, m), 3.34-3.41 (1H,m), 3.49-3.56 (1H, m), 3.90 (3H, s), 4.36-4.41 (1H, m), 6.98-7.06 (1H,m), 7.11-7.17 (1H, m), 7.47-7.54 (1H, m), 7.89-7.96 (1H, m), 7.99-8.05(2H, m), 8.13 (1H, br s), 8.70-8.80 (1H, m).

ESI-MS (m/e): 403.2 [M+H]⁺

Example 47 Synthesis of(1R*,4S*,6R*)-N-(5-Isopropoxypyridin-2-yl)-2-(pyridin-2-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 44, using the titlecompound of Production Example 5 and the title compound of ProductionExample 20 as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.34 (6H, d, J=6.1 Hz), 1.52-1.96 (5H, m),2.02-2.10 (1H, m), 2.16-2.29 (1H, m), 3.05-3.15 (1H, m), 3.26-3.34 (1H,m), 3.52-3.60 (1H, m), 4.32-4.38 (1H, m), 4.47-4.57 (1H, m), 7.21-7.26(1H, m), 7.50-7.58 (1H, m), 7.90-7.99 (2H, m), 8.01-8.11 (2H, m), 8.33(1H, br s), 8.82-8.88 (1H, m).

ESI-MS (m/e): 431.3 [M+H]⁺

Example 48 Synthesis of(1R*,4S*,6R*)-N-(5-isopropoxypyridin-2-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 6 and the title compound ofProduction Example 20 as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.33 (6H, d, J=6.3 Hz), 1.51-1.65 (2H, m),1.69-1.85 (2H, m), 1.89-2.09 (2H, m), 2.13-2.22 (1H, m), 3.02-3.14 (2H,m), 3.43-3.51 (1H, m), 3.79 (3H, s), 4.28-4.33 (1H, m), 4.45-4.55 (1H,m), 7.20-7.25 (1H, m), 7.47-7.50 (1H, m), 7.64-7.68 (1H, m), 7.92-7.98(1H, m), 8.02-8.09 (1H, m), 9.02 (1H, br s).

ESI-MS (m/e): 434.3 [M+H]⁺

Example 49 Synthesis of(1R*,4S*,6R*)-N-(3-Cyclopropyl-1H-pyrazol-5-yl)-2-(pyridin-2-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 5 and5-cyclopropyl-1H-pyrazole-3-amine as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.72-0.79 (2H, m), 0.84-0.95 (2H, m),1.36-1.52 (2H, m), 1.56-1.65 (1H, m), 1.74-1.90 (3H, m), 2.00-2.08 (1H,m), 2.30-2.40 (1H, m), 3.20-3.30 (1H, m), 3.44-3.54 (2H, m), 4.26-4.33(1H, m), 6.37 (1H, s), 7.49-7.57 (1H, m), 7.90-7.96 (1H, m), 7.99-8.04(1H, m), 8.66-8.75 (1H, m), 11.51 (1H, br s).

ESI-MS (m/e): 402.3 [M+H]⁺

Example 50 Optical Resolution of(1R*,4S*,6R*)-N-(5-Isopropoxypyridin-2-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The compound (561 mg, 1.29 mmol)synthesized in Example 48 was opticallyresolved using normal-phase chiral HPLC(CHIRALPAK OD 2 cm 0×25 cmL(Daicel Chemical Industries, Ltd.); mobile phase: hexane:ethanol=70:30;flow rate: 10 ml/min; isogradient), and(1R**,4S**,6R**)-N-(5-isopropoxypyridin-2-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide(retention time: 22 min; 109 mg), and(1S**,4R**,6S**)-N-(5-isopropoxypyridin-2-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide(retention time: 48.5 min; 115 mg) were obtained.

Example 51 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 2 and5-methyl-1,3,4-thiadiazole-2-sulfonyl chloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.31 (6H, d, J=6.1 Hz), 1.55-1.76 (2H, m),1.78-1.97 (3H, m), 2.11-2.16 (1H, m), 2.23-2.31 (1H, m), 2.88 (3H, s),3.06-3.14 (1H, m), 3.33-3.40 (1H, m), 3.57-3.65 (1H, m), 4.26-4.34 (1H,m), 4.44-4.56 (1H, m), 6.82-6.88 (2H, m), 7.42-7.47 (2H, m), 7.77 (1H,br s).

ESI-MS (m/e): 451.2 [M+H]⁺

Example 52 Synthesis of(1R*,4S*,6R*)-N-(2-Isopropoxyphenyl)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 44, using the titlecompound of Production Example 4 and 2-isopropoxyaniline as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.44 (6H, d, J=5.9 Hz), 1.54-1.83 (4H, m),2.02-2.08 (1H, m), 2.14-2.22 (1H, m), 2.80-2.88 (1H, m), 3.30-3.46 (2H,m), 4.07-4.15 (1H, m), 4.55-4.68 (1H, m), 6.87-6.96 (2H, m), 6.99-7.07(1H, m), 7.50-7.63 (3H, m), 7.83 (1H, br s), 7.86-7.94 (2H, m),8.23-8.32 (1H, m).

ESI-MS (m/e): 429.3 [M+H]⁺

Example 53 Synthesis of(1R*,4S*,6R*)-N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 44, using the titlecompound of Production Example 4 and5-tert-butyl-1,3,4-thiadiazole-2-amine as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.48 (9H, s), 1.55-1.69 (2H, m), 1.83-2.00(3H, m), 2.03-2.10 (1H, m), 2.20-2.31 (1H, m), 3.32-3.42 (2H, m),3.46-3.53 (1H, m), 4.15-4.19 (1H, m), 7.44-7.58 (3H, m), 7.83-7.89 (2H,m).

ESI-MS (m/e): 435.3 [M+H]⁺

Example 54 Synthesis of(1R*,4S*,6R*)-N-(3-Isopropyl-1,2,4-thiadiazol-5-yl)-2-(phenylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 44, using the titlecompound of Production Example 4 and3-isopropyl-1,2,4-thiadiazole-5-amine as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.29-1.44 (7H, m), 1.47-1.71 (2H, m),1.78-1.87 (1H, m), 2.06-2.13 (1H, m), 2.18-2.28 (1H, m), 3.09-3.22 (2H,m), 3.25-3.31 (1H, m), 3.47-3.53 (1H, m), 4.12-4.18 (1H, m), 7.51-7.57(2H, m), 7.58-7.64 (1H, m), 7.87-7.92 (2H, m).

ESI-MS (m/e): 421.3 [M+H]⁺

Example 55 Synthesis of(1R*,4S*,6R*)-2-(Phenylsulfonyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 44, using the titlecompound of Production Example 4 and5-(trifluoromethyl)-1,3,4-thiadiazole-2-amine as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.32-1.45 (1H, m), 1.51-1.77 (3H, m),1.97-2.16 (3H, m), 3.27-3.38 (2H, m), 3.45-3.52 (1H, m), 4.18-4.28 (1H,m), 7.46-7.60 (3H, m), 7.84-7.90 (2H, m).

ESI-MS (m/e): 447.2 [M+H]⁺

Example 56 Synthesis of(1R*,4S*,6R*)-N-(6-Isopropoxypyridin-3-yl)-2-(pyridin-2-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 5 and6-isopropoxypyridine-3-amine as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.33 (6H, d, J=6.3 Hz), 1.46-1.55 (1H, m),1.57-1.66 (1H, m), 1.69-1.85 (2H, m), 2.02-2.08 (1H, m), 2.19-2.22 (1H,m), 2.23-2.30 (1H, m), 3.05-3.18 (1H, m), 3.25-3.35 (1H, m), 3.45-3.56(1H, m), 4.27-4.34 (1H, m), 5.19-5.30 (1H, m), 6.62-6.69 (1H, m),7.51-7.56 (1H, m), 7.80 (1H, br s), 7.84-7.89 (1H, m), 7.92-7.98 (1H,m), 8.02-8.06 (1H, m), 8.16-8.22 (1H, m), 8.68-8.77 (1H, m).

ESI-MS (m/e): 431.3 [M+H]⁺

Example 57 Synthesis of(1R*,4S*,6R*)-N-(6-Isopropoxypyridin-3-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Reference Example 1(2), usingthe title compound of Production Example 6 and6-isopropoxypyridine-3-amine as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.33 (6H, d, J=6.3 Hz), 1.45-1.52 (1H, m),1.55-1.67 (1H, m), 1.72-1.83 (2H, m), 1.90-2.07 (2H, m), 2.14-2.22 (1H,m), 2.93-3.08 (2H, m), 3.37-3.50 (1H, m), 3.80 (3H, s), 4.27-4.33 (1H,m), 5.16-5.29 (1H, m), 6.63-6.68 (1H, m), 7.49-7.52 (1H, m), 7.58-7.61(1H, m), 7.89-7.96 (1H, m), 8.20-8.28 (1H, m), 8.73 (1H, br s).

ESI-MS (m/e): 434.3 [M+H]⁺

Example 58 Synthesis ofN-{[1-(Ethylsulfonyl)-3-phenylpiperidin-3-yl]methyl}-2-methoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and ethanesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.35 (3H, t, J=7.3 Hz), 1.56-1.64 (1H, m),1.77-1.87 (2H, m), 2.11-2.20 (1H, m), 2.88-2.99 (2H, m), 3.08-3.16 (1H,m), 3.25-3.30 (1H, m), 3.37-3.45 (1H, m), 3.56 (3H, s), 3.73-3.84 (2H,m), 3.92-3.99 (1H, m), 6.82-6.87 (1H, m), 6.99-7.06 (1H, m), 7.27-7.33(1H, m), 7.36-7.46 (3H, m), 7.49-7.59 (3H, m), 8.10-8.15 (1H, m).

ESI-MS (m/e): 417.0 [M+H]⁺

Example 59 Synthesis of2-Methoxy-N-{[3-phenyl-1-(propylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 1-propanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.03 (3H, t, J=7.6 Hz), 1.54-1.65 (1H, m),1.76-1.89 (4H, m), 2.11-2.21 (1H, m), 2.77-2.93 (2H, m), 3.03-3.12 (1H,m), 3.18-3.25 (1H, m), 3.37-3.46 (1H, m), 3.56 (3H, s), 3.70-3.86 (2H,m), 3.94-4.01 (1H, m), 6.81-6.87 (1H, m), 7.00-7.05 (1H, m), 7.27-7.33(1H, m), 7.36-7.46 (3H, m), 7.50-7.58 (3H, m), 8.10-8.15 (1H, m).

ESI-MS (m/e): 431.0 [M+H]⁺

Example 60 Synthesis of2-Methoxy-N-{[1-(methylsulfonyl)-3-phenylpiperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and methanesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.54-1.64 (1H, m), 1.73-1.86 (2H, m),2.15-2.24 (1H, m), 2.76 (3H, s), 2.92-3.03 (1H, m), 3.08-3.15 (1H, m),3.40-3.47 (1H, m), 3.56 (3H, s), 3.66-3.73 (1H, m), 3.82-3.89 (1H, m),3.98-4.04 (1H, m), 6.82-6.87 (1H, m), 6.99-7.06 (1H, m), 7.28-7.33 (1H,m), 7.36-7.46 (3H, m), 7.50-7.59 (3H, m), 8.10-8.15 (1H, m).

ESI-MS (m/e): 403.2 [M+H]⁺

Example 61 Synthesis of N-{[1-(Butylsulfonyl)-3-phenylpiperidin-3-yl]methyl}-2-methoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 1-butanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.93 (3H, t, J=7.3 Hz), 1.36-1.48 (2H, m),1.55-1.64 (1H, m), 1.72-1.85 (4H, m), 2.12-2.21 (1H, m), 2.80-2.94 (2H,m), 3.04-3.13 (1H, m), 3.19-3.25 (1H, m), 3.37-3.46 (1H, m), 3.56 (3H,s), 3.71-3.85 (2H, m), 3.95-4.02 (1H, m), 6.82-6.87 (1H, m), 6.99-7.06(1H, m), 7.27-7.33 (3H, m), 7.36-7.46 (3H, m), 7.49-7.59 (3H, m),8.09-8.16 (1H, m).

ESI-MS (m/e): 445.1 [M+H]⁺

Example 62 Synthesis of2-Methoxy-N-{[3-phenyl-1-(phenylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and benzenesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.50-1.65 (2H, m), 1.69-1.81 (1H, m),2.01-2.12 (1H, m), 2.57-2.69 (1H, m), 2.75-2.84 (1H, m), 3.25-3.37 (1H,m), 3.59 (3H, s), 3.64-3.78 (2H, m), 3.86-3.99 (1H, m), 6.83-6.89 (1H,m), 7.00-7.07 (1H, m), 7.28-7.34 (1H, m), 7.37-7.47 (3H, m), 7.48-7.63(6H, m), 7.73-7.78 (2H, m), 8.12-8.16 (1H, m).

ESI-MS (m/e): 465.0 [M+H]⁺

Example 63 Synthesis of2-Methoxy-N-({1-[(2-methylphenyl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 2-methylbenzenesulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.55-1.67 (2H, m), 1.72-1.87 (2H, m),2.04-2.15 (1H, m), 2.52-2.56 (3H, m), 2.93-3.02 (1H, m), 3.09-3.15 (1H,m), 3.29-3.36 (1H, m), 3.55-3.58 (3H, m), 3.70-3.92 (2H, m), 6.82-6.89(1H, m), 7.01-7.07 (1H, m), 7.23-7.52 (9H, m), 7.54-7.66 (1H, m),7.85-7.91 (1H, m), 8.11-8.18 (1H, m).

ESI-MS (m/e): 479.1 [M+H]⁺

Example 64 Synthesis of2-Methoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and pyridine-2-sulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.53-1.66 (1H, m), 1.68-1.85 (2H, m),2.09-2.17 (1H, m), 3.03-3.14 (1H, m), 3.18-3.25 (1H, m), 3.47-3.56 (1H,m), 3.59 (3H, s), 3.63-3.71 (1H, m), 3.77-3.87 (1H, m), 4.05-4.14 (1H,m), 6.82-6.88 (1H, m), 6.98-7.06 (1H, m), 7.28-7.33 (1H, m), 7.36-7.51(4H, m), 7.52-7.60 (3H, m), 7.87-7.95 (2H, m), 8.09-8.14 (1H, m),8.70-8.73 (1H, m).

ESI-MS (m/e): 466.0 [M+H]⁺

Example 65 Synthesis of2-Methoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 1-methyl-1H-imidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.50-1.60 (1H, m), 1.63-1.81 (2H, m),2.08-2.16 (1H, m), 2.90-3.02 (2H, m), 3.46-3.55 (1H, m), 3.58 (3H, s),3.66-3.81 (5H, m), 3.97-4.06 (1H, m), 6.83-6.88 (1H, m), 6.99-7.05 (1H,m), 7.28-7.32 (1H, m), 7.35-7.45 (4H, m), 7.46-7.51 (1H, m), 7.52-7.61(3H, m), 8.08-8.15 (1H, m).

ESI-MS (m/e): 469.2 [M+H]⁺

Example 66 Synthesis ofN-({1-[(2-Chlorophenyl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-2-methoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 2-chlorobenzenesulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.62-1.72 (1H, m), 1.76-1.94 (2H, m),2.02-2.12 (1H, m), 3.08-3.18 (1H, m), 3.28-3.39 (2H, m), 3.52-3.62 (4H,m), 3.80-3.96 (2H, m), 6.82-6.88 (1H, m), 6.99-7.06 (1H, m), 7.27-7.32(1H, m), 7.34-7.42 (4H, m), 7.43-7.48 (3H, m), 7.49-7.57 (2H, m),7.99-8.04 (1H, m), 8.10-8.16 (1H, m).

ESI-MS (m/e): 499.0 [M+H]⁺

Example 67 Synthesis ofN-({1-[(3-Chlorophenyl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-2-methoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 3-chlorobenzenesulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.54-1.69 (2H, m), 1.75-1.85 (1H, m),2.05-2.15 (1H, m), 2.63-2.77 (1H, m), 2.80-2.90 (1H, m), 3.24-3.35 (1H,m), 3.59 (3H, s), 3.64-3.72 (1H, m), 3.73-3.82 (1H, m), 3.84-3.94 (1H,m), 6.83-6.90 (1H, m), 7.01-7.08 (1H, m), 7.28-7.35 (1H, m), 7.36-7.60(8H, m), 7.61-7.66 (1H, m), 7.72-7.76 (1H, m), 8.12-8.19 (1H, m).

ESI-MS (m/e): 499.0 [M+H]⁺

Example 68 Synthesis ofN-({1-[(4-Chlorophenyl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-2-methoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 4-chlorobenzenesulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.49-1.67 (2H, m), 1.72-1.82 (1H, m),2.04-2.15 (1H, m), 2.57-2.69 (1H, m), 2.75-2.86 (1H, m), 3.25-3.35 (1H,m), 3.58 (3H, s), 3.66-3.76 (2H, m), 3.86-3.95 (1H, m), 6.82-6.90 (1H,m), 7.01-7.08 (1H, m), 7.29-7.35 (1H, m), 7.37-7.58 (8H, m), 7.65-7.72(2H, m), 8.11-8.17 (1H, m).

ESI-MS (m/e): 499.0 [M+H]⁺

Example 69 Synthesis of2-Methoxy-N-({1-[3-methoxyphenyl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 3-methoxybenzenesulfonyl chlorideas the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.49-1.67 (2H, m), 1.71-1.79 (1H, m),2.04-2.14 (1H, m), 2.57-2.67 (1H, m), 2.74-2.83 (1H, m), 3.28-3.39 (1H,m), 3.59 (3H, s), 3.67-3.75 (2H, m), 3.85 (3H, s), 3.91-3.98 (1H, m),6.84-6.89 (1H, m), 7.00-7.06 (1H, m), 7.09-7.14 (1H, m), 7.22-7.25 (1H,m), 7.29-7.35 (2H, m), 7.37-7.47 (4H, m), 7.50-7.59 (3H, m), 8.10-8.15(1H, m).

ESI-MS (m/e): 495.0 [M+H]⁺

Example 70 Synthesis of2-Methoxy-N-({1-[4-methoxyphenyl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 8 and 4-methoxybenzenesulfonyl chlorideas the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.48-1.65 (2H, m), 1.68-1.81 (1H, m),2.01-2.13 (1H, m), 2.54-2.65 (1H, m), 2.71-2.81 (1H, m), 3.26-3.36 (1H,m), 3.59 (3H, s), 3.66-3.77 (2H, m), 3.87 (3H, s), 3.89-3.97 (1H, m),6.83-6.89 (1H, m), 6.96-7.08 (3H, m), 7.28-7.34 (1H, m), 7.37-7.47 (3H,m), 7.48-7.53 (1H, m), 7.54-7.59 (2H, m), 7.66-7.72 (2H, m), 8.10-8.16(1H, m).

ESI-MS (m/e): 495.1 [M+H]⁺

Example 71 Synthesis of4-Isopropoxy-N-{[3-phenyl-1-(propylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 9 and 1-propanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.04 (3H, t, J=7.6 Hz), 1.33 (6H, d, J=6.3Hz), 1.62-1.70 (1H, m), 1.77-1.94 (4H, m), 2.06-2.16 (1H, m), 2.81-2.94(2H, m), 3.20-3.33 (2H, m), 3.40-3.47 (1H, m), 3.62-3.70 (1H, m),3.73-3.84 (2H, m), 4.51-4.63 (1H, m), 5.77-5.85 (1H, m), 6.79-6.85 (2H,m), 7.25-7.32 (1H, m), 7.38-7.54 (6H, m).

ESI-MS (m/e): 459.1 [M+H]⁺

Example 72 Synthesis of4-Isopropoxy-N-{[3-phenyl-1-(phenylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 9 and benzenesulfonyl chloride as the rawmaterial.

1H-NMR (400 MHz, CDCl₃, δ): 1.34 (6H, d, J=5.9 Hz), 1.64-1.72 (1H, m),1.78-1.88 (1H, m), 1.98-2.08 (1H, m), 2.77-2.88 (1H, m), 2.96-3.06 (1H,m), 3.12-3.22 (1H, m), 3.55-3.63 (1H, m), 3.66-3.82 (2H, m), 4.52-4.64(1H, m), 5.66-5.74 (1H, m), 6.80-6.87 (2H, m), 7.28-7.34 (1H, m),7.40-7.64 (10H, m), 7.75-7.80 (2H, m).

ESI-MS (m/e): 493.0 [M+H]⁺

Example 73 Synthesis of4-Isopropoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 9 and pyridine-2-sulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.33 (6H, d, J=5.9 Hz), 1.58-1.71 (1H, m),1.78-1.94 (2H, m), 2.02-2.12 (1H, m), 3.23-3.41 (2H, m), 3.44-3.51 (1H,m), 3.53-3.60 (1H, m), 3.80-3.94 (2H, m), 4.51-4.64 (1H, m), 5.73-5.89(1H, m), 6.80-6.85 (2H, m), 7.24-7.32 (1H, m), 7.37-7.45 (2H, m),7.47-7.56 (5H, m), 7.89-7.99 (2H, m), 8.67-8.75 (1H, m).

ESI-MS (m/e): 494.1 [M+H]⁺

Example 74 Synthesis of4-Isopropoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 9 and 1-methyl-1H-imidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.33 (6H, d, J=5.9 Hz), 1.55-1.69 (1H, m),1.71-1.90 (2H, m), 2.02-2.10 (1H, m), 3.10-3.18 (1H, m), 3.21-3.27 (1H,m), 3.31-3.38 (1H, m), 3.55-3.63 (1H, m), 3.72-3.83 (4H, m), 4.53-4.62(1H, m), 5.75-5.84 (1H, m), 6.79-6.86 (2H, m), 7.26-7.31 (1H, m),7.38-7.45 (3H, m), 7.47-7.54 (5H, m).

ESI-MS (m/e): 497.0 [M+H]⁺

Example 75N-(2-Methoxyphenyl)-N′-{[3-phenyl-1-(phenylsulfonyl)piperidin-3-yl]methyl}urea

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 18 and benzenesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.70-1.82 (1H, m), 1.98-2.06 (1H, m),2.63-2.74 (1H, m), 2.79-2.87 (1H, m), 3.19-3.33 (1H, m), 3.40-3.48 (1H,m), 3.50-3.59 (1H, m), 3.78-3.88 (4H, m), 4.27-4.36 (1H, m), 6.52-6.60(1H, m), 6.80-6.90 (2H, m), 6.94-7.03 (1H, m), 7.24-7.31 (1H, m),7.36-7.43 (2H, m), 7.45-7.49 (2H, m), 7.51-7.64 (3H, m), 7.73-7.82 (3H,m).

ESI-MS (m/e): 480.0 [M+H]⁺

Example 76 Synthesis of5-Isopropoxy-N-{[3-phenyl-1-(propylsulfonyl)piperidin-3-yl]methyl}pyridine-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 10 and 1-propanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.02 (3H, t, J=7.3 Hz), 1.36 (6H, d, J=5.9Hz), 1.56-1.69 (1H, m), 1.76-1.90 (4H, m), 2.13-2.22 (1H, m), 2.73-2.92(2H, m), 3.06-3.18 (1H, m), 3.24-3.40 (2H, m), 3.60-3.68 (1H, m),3.71-3.79 (1H, m), 3.84-3.95 (1H, m), 4.55-4.70 (1H, m), 7.18-7.24 (1H,m), 7.27-7.32 (1H, m), 7.36-7.43 (2H, m), 7.44-7.50 (2H, m), 7.57-7.65(1H, m), 8.02-8.08 (2H, m).

ESI-MS (m/e): 460.0 [M+H]⁺

Example 77 Synthesis of5-Isopropoxy-N-{[3-phenyl-1-(phenylsulfonyl)piperidin-3-yl]methyl}pyridine-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 10 and benzenesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.36 (6H, d, J=6.3 Hz), 1.53-1.70 (2H, m),1.76-1.86 (1H, m), 2.01-2.11 (1H, m), 2.65-2.79 (1H, m), 2.88-2.97 (1H,m), 3.12-3.26 (1H, m), 3.47-3.59 (1H, m), 3.69-3.83 (2H, m), 4.56-4.67(1H, m), 7.20-7.24 (1H, m), 7.27-7.33 (1H, m), 7.38-7.45 (2H, m),7.46-7.63 (6H, m), 7.74-7.79 (2H, m), 8.02-8.09 (2H, m).

ESI-MS (m/e): 494.0 [M+H]⁺

Example 78 Synthesis of5-Isopropoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}pyridine-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 10 and pyridine-2-sulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.36 (6H, d, J=6.3 Hz), 1.56-1.92 (3H, m),2.06-2.16 (1H, m), 3.06-3.22 (1H, m), 3.27-3.46 (2H, m), 3.49-3.58 (1H,m), 3.80-3.88 (1H, m), 3.92-4.02 (1H, m), 4.57-4.68 (1H, m), 7.15-7.23(1H, m), 7.25-7.32 (1H, m), 7.37-7.43 (2H, m), 7.46-7.53 (3H, m),7.56-7.65 (1H, m), 7.87-7.96 (2H, m), 8.01-8.08 (2H, m), 8.68-8.73 (1H,m).

ESI-MS (m/e): 495.0 [M+H]⁺

Example 79 Synthesis of5-Isopropoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)pyridine-2-carboxamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 10 and 1-methyl-1H-imidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.36 (6H, d, J=6.3 Hz), 1.53-1.65 (1H, m),1.68-1.86 (2H, m), 2.06-2.15 (1H, m), 2.97-3.07 (1H, m), 3.09-3.17 (1H,m), 3.34-3.42 (1H, m), 3.50-3.59 (1H, m), 3.76 (3H, s), 3.77-3.92 (2H,m), 4.56-4.67 (1H, m), 7.16-7.22 (1H, m), 7.25-7.31 (1H, m), 7.36-7.43(3H, m), 7.47-7.52 (3H, m), 7.56-7.63 (1H, m), 8.00-8.06 (2H, m).

ESI-MS (m/e): 498.0 [M+H]⁺

Example 80 Synthesis of4-Isopropoxy-N-{[3-methyl-1-(propylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 11 and 1-propanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.88 (3H, t, J=7.3 Hz), 1.33 (6H, d, J=6.3Hz), 1.35-1.46 (2H, m), 1.50-1.61 (1H, m), 1.63-1.84 (4H, m), 1.86-2.07(3H, m), 2.15-2.26 (1H, m), 2.89-3.07 (2H, m), 3.13-3.26 (2H, m),4.46-4.56 (1H, m), 7.19-7.25 (1H, m), 7.93-7.99 (1H, m), 8.03-8.09 (1H,m), 8.36-8.44 (1H, m).

ESI-MS (m/e): 397.3 [M+H]⁺

Example 81 Synthesis of4-Isopropoxy-N-{[3-methyl-1-(phenylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 11 and benzenesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.20-1.31 (1H, m), 1.36 (6H, d, J=6.3 Hz),1.54-1.61 (1H, m), 1.64-1.71 (1H, m), 1.85-1.98 (1H, m), 2.22-2.30 (1H,m), 2.57-2.67 (1H, m), 3.32-3.40 (2H, m), 3.52-3.61 (1H, m), 3.69-3.77(1H, m), 4.57-4.68 (1H, m), 6.62-6.70 (1H, m), 6.90-6.96 (2H, m),7.51-7.64 (3H, m), 7.75-7.86 (4H, m).

ESI-MS (m/e): 431.2 [M+H]⁺

Example 82 Synthesis of4-Isopropoxy-N-{[3-methyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 11 and pyridine-2-sulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.95 (3H, s), 1.35 (6H, d, J=5.9 Hz),1.58-1.72 (1H, m), 1.81-1.97 (1H, m), 2.56-2.64 (1H, m), 2.89-2.98 (1H,m), 3.31-3.40 (1H, m), 3.59-3.66 (1H, m), 3.71-3.81 (2H, m), 4.54-4.66(1H, m), 6.76-6.85 (1H, m), 6.87-6.94 (2H, m), 7.46-7.53 (1H, m),7.80-7.85 (2H, m), 7.88-7.98 (2H, m), 8.66-8.72 (1H, m).

ESI-MS (m/e): 432.2 [M+H]⁺

Example 83 Synthesis of4-Isopropoxy-N-({3-methyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-3-yl}methyl)benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 11 and 1-methyl-1H-imidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.23-1.37 (7H, m), 1.53-1.68 (2H, m),1.81-1.93 (1H, m), 2.46-2.56 (1H, m), 2.77-2.88 (1H, m), 3.28-3.37 (1H,m), 3.51-3.58 (1H, m), 3.60-3.79 (5H, m), 4.54-4.66 (1H, m), 6.75-6.84(1H, m), 6.87-6.92 (2H, m), 7.41-7.50 (2H, m), 7.79-7.86 (2H, m).

ESI-MS (m/e): 435.2 [M+H]⁺

Example 84 Synthesis ofN-{[3-Ethyl-1-(propylsulfonyl)piperidin-3-yl]methyl}-4-isopropoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 12 and 1-propanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.34 (7H, d, J=6.3 Hz), 1.39-1.64 (3H, m),1.76-1.88 (1H, m), 1.92-2.07 (2H, m), 2.10-2.17 (1H, m), 2.19-2.37 (2H,m), 3.52-3.66 (1H, m), 4.55-4.66 (1H, m), 5.65 (1H, s), 7.55-7.61 (1H,m), 7.94-8.02 (1H, m), 8.08-8.14 (1H, m), 8.41 (1H, br s), 8.74-8.80(1H, m).

ESI-MS (m/e): 411.3 [M+H]⁺

Example 85 Synthesis ofN-{[3-Ethyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}-4-isopropoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 12 and pyridine-2-sulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.95 (3H, t, J=7.3 Hz), 1.08-1.20 (1H, m),1.27-1.47 (7H, m), 1.63-1.73 (1H, m), 1.82-1.96 (1H, m), 2.56-2.65 (1H,m), 2.85-2.97 (1H, m), 3.26-3.35 (1H, m), 3.59-3.67 (1H, m), 3.75-3.93(2H, m), 4.54-4.68 (1H, m), 6.79-6.86 (1H, m), 6.88-6.93 (2H, m),7.45-7.53 (1H, m), 7.80-7.88 (2H, m), 7.89-8.00 (2H, m), 8.67-8.73 (1H,m).

ESI-MS (m/e): 446.2 [M+H]⁺

Example 86 Synthesis ofN-({3-Ethyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-3-yl}methyl)-4-isopropoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 12 and 1-methyl-1H-imidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.94 (3H, t, J=7.3 Hz), 1.09-1.21 (1H, m),1.30-1.37 (6H, m), 1.38-1.46 (1H, m), 1.54-1.71 (1H, m), 1.79-1.94 (1H,m), 2.45-2.54 (1H, m), 2.74-2.84 (1H, m), 3.24-3.33 (1H, m), 3.53-3.60(1H, m), 3.67-3.77 (4H, m), 3.80-3.89 (1H, m), 4.54-4.65 (1H, m),6.76-6.84 (1H, m), 6.87-6.92 (2H, m), 7.43-7.49 (2H, m), 7.80-7.87 (2H,m).

ESI-MS (m/e): 449.2 [M+H]⁺

Example 87 Synthesis of4-Isopropoxy-N-{[3-isopropyl-1-(propylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 13 and 1-propanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.90 (3H, d, J=7.3 Hz), 1.00 (3H, d, J=6.8Hz), 1.08 (3H, t, J=7.3 Hz), 1.26-1.44 (7H, m), 1.55-1.73 (2H, m),1.81-1.96 (2H, m), 2.66-2.81 (2H, m), 2.89-2.98 (2H, m), 3.22-3.32 (1H,m), 3.56-3.66 (1H, m), 3.77-3.86 (1H, m), 3.97-4.08 (1H, m), 4.55-4.65(1H, m), 6.87-6.92 (2H, m), 6.94-7.01 (1H, m), 7.78-7.85 (2H, m).

ESI-MS (m/e): 425.2 [M+H]⁺

Example 88 Synthesis of4-Isopropoxy-N-{[3-isopropyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 13 and pyridine-2-sulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.86 (3H, d, J=6.8 Hz), 0.99 (3H, d, J=6.8Hz), 1.29-1.41 (7H, m), 1.53-1.73 (5H, m), 1.86-2.00 (1H, m), 2.67-2.74(1H, m), 2.76-2.86 (1H, m), 3.29-3.38 (1H, m), 3.73-3.80 (1H, m),3.86-3.94 (1H, m), 4.00-4.11 (1H, m), 4.55-4.65 (1H, m), 6.88-6.93 (2H,m), 6.96-7.03 (1H, m), 7.49-7.54 (1H, m), 7.85-7.90 (2H, m), 7.91-8.00(2H, m), 8.67-8.75 (1H, m).

ESI-MS (m/e): 460.2 [M+H]⁺

Example 89 Synthesis of4-Isopropoxy-N-({3-isopropyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-3-yl}methyl)benzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 13 and 1-methyl-1H-imidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.86 (3H, d, J=6.8 Hz), 0.98 (3H, d, J=6.8Hz), 1.25-1.38 (7H, m), 1.49-1.58 (1H, m), 1.61-1.72 (2H, m), 1.85-1.99(1H, m), 2.54-2.61 (1H, m), 2.63-2.72 (1H, m), 3.25-3.37 (1H, m),3.66-3.86 (5H, m), 3.95-4.07 (1H, m), 4.54-4.65 (1H, m), 6.85-6.99 (3H,m), 7.44-7.51 (2H, m), 7.83-7.90 (2H, m).

ESI-MS (m/e): 463.3 [M+H]⁺

Example 90 Synthesis ofN-{[3-Benzyl-1-(propylsulfonyl)piperidin-3-yl]methyl}-4-isopropoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 14 and 1-propanesulfonyl chloride as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.06 (3H, t, J=7.6 Hz), 1.36 (6H, d, J=5.9Hz), 1.41-1.54 (2H, m), 1.63-1.73 (1H, m), 1.78-1.92 (3H, m), 2.52-2.63(1H, m), 2.72-2.97 (5H, m), 3.34-3.51 (2H, m), 3.52-3.60 (1H, m),3.78-3.87 (1H, m), 4.55-4.67 (1H, m), 6.57-6.68 (1H, m), 6.85-6.92 (2H,m), 7.23-7.36 (5H, m), 7.65-7.71 (2H, m).

ESI-MS (m/e): 473.2 [M+H]⁺

Example 91 Synthesis ofN-{[3-benzyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}-4-isopropoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 14 and pyridine-2-sulfonyl chloride asthe raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.35 (7H, d, J=6.3 Hz), 1.38-1.52 (2H, m),1.65-1.74 (1H, m), 1.79-1.92 (1H, m), 2.52-2.60 (1H, m), 2.78-2.88 (2H,m), 2.90-3.00 (1H, m), 3.33-3.41 (1H, m), 3.56-3.69 (2H, m), 3.85-3.94(1H, m), 4.55-4.67 (1H, m), 6.58-6.70 (1H, m), 6.85-6.93 (2H, m),7.20-7.34 (5H, m), 7.46-7.54 (1H, m), 7.69-7.76 (2H, m), 7.88-8.00 (2H,m), 8.64-8.72 (1H, m).

ESI-MS (m/e): 508.2 [M+H]⁺

Example 92 Synthesis ofN-({3-Benzyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-3-yl}methyl)-4-isopropoxybenzamide

The title compound was synthesized as in Example 13, using the titlecompound of Production Example 14 and 1-methyl-1H-imidazole-4-sulfonylchloride as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.31-1.38 (7H, m), 1.40-1.49 (1H, m),1.65-1.89 (2H, m), 2.50-2.57 (1H, m), 2.71-2.79 (1H, m), 2.82-2.94 (2H,m), 3.30-3.37 (1H, m), 3.44-3.56 (2H, m), 3.75 (3H, s), 3.79-3.88 (1H,m), 4.57-4.66 (1H, m), 6.51-6.61 (1H, m), 6.84-6.91 (2H, m), 7.21-7.27(1H, m), 7.28-7.35 (4H, m), 7.41-7.49 (2H, m), 7.67-7.73 (2H, m).

ESI-MS (m/e): 511.2 [M+H]⁺

Example 93 Synthesis of3-Methyl-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide

Diisopropylethylamine (0.02 mL, 0.112 mmol) and HATU (37 mg, 0.097 mmol)were added to a DMF (1 mL) solution of the title compound (25 mg, 0.075mmol) of Production Example 15 and 3-methyl-1H-pyrazole-5-carboxylicacid (10 mg, 0.079 mmol), and the mixture was stirred at roomtemperature for 24 hours. The reaction mixture was diluted with ethylacetate, and washed twice with distilled water, and once with saturatedbrine. The organic layer was dried over magnesium sulfate, andconcentrated under reduced pressure. The resulting residue was thenpurified using silica gel column chromatography to obtain the titlecompound (12 mg, 36%).

1H-NMR (CD3OD) δ: 1.51-1.63 (1H, m), 1.69-1.88 (2H, m), 2.07-2.19 (1H,m), 2.31 (3H, s), 2.89-2.96 (1H, m), 3.01-3.08 (1H, m), 3.49-3.56 (1H,m), 3.68-3.74 (1H, m), 3.78-3.85 (4H, m), 6.42 (1H, s), 7.25-7.31 (1H,m), 7.37-7.44 (2H, m), 7.52-7.57 (2H, m), 7.72-7.75 (1H, m), 7.77-7.80(1H, m).

ESI-MS (m/e): 443.2 [M+H]⁺

Example 94 Synthesis of3-Ethyl-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and 3-ethyl-1H-pyrazole-5-carboxylicacid as the raw material.

1H-NMR (CD3OD) δ: 1.28 (3H, t, J=7.6 Hz), 1.50-1.63 (1H, m), 1.68-1.87(2H, m), 2.07-2.18 (1H, m), 2.70 (2H, q, J=7.6 Hz), 2.86-2.97 (1H, m),3.00-3.08 (1H, m), 3.48-3.57 (1H, m), 3.68-3.74 (1H, m), 3.77-3.86 (4H,m), 6.45 (1H, s), 7.25-7.31 (1H, m), 7.37-7.43 (2H, m), 7.52-7.57 (2H,m), 7.73-7.75 (1H, m), 7.77-7.79 (1H, m).

ESI-MS (m/e): 457.2 [M+H]⁺

Example 95 Synthesis of3-Isopropyl-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and3-isopropyl-1H-pyrazole-5-carboxylic acid as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.26 (6H, dd, J=7.0, 2.0 Hz), 1.50-1.62 (1H,m), 1.66-1.85 (2H, m), 2.02-2.14 (1H, m), 2.93-3.05 (2H, m), 3.08-3.16(1H, m), 3.32-3.40 (1H, m), 3.50-3.59 (1H, m), 3.62-3.70 (1H, m), 3.75(3H, s), 3.79-3.86 (1H, m), 6.49 (1H, s), 6.62-6.71 (1H, m), 7.21-7.28(1H, m), 7.34-7.40 (2H, m), 7.45-7.53 (3H, m).

ESI-MS (m/e): 471.2 [M+H]⁺

Example 96 Synthesis of3-Cyclopropyl-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and3-cyclopropyl-1H-pyrazole-5-carboxylic acid as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.66-0.72 (2H, m), 0.92-0.99 (2H, m),1.51-1.63 (1H, m), 1.66-1.90 (3H, m), 2.02-2.13 (1H, m), 2.95-3.04 (1H,m), 3.10-3.18 (1H, m), 3.31-3.39 (1H, m), 3.50-3.58 (1H, m), 3.62-3.70(1H, m), 3.75 (3H, s), 3.77-3.84 (1H, m), 6.31 (1H, s), 6.61-6.70 (1H,m), 7.21-7.29 (1H, m), 7.33-7.40 (2H, m), 7.41-7.52 (4H, m).

ESI-MS (m/e): 469.2 [M+H]⁺

Example 97 Synthesis ofN-({1-[(1-Methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and3-trifluoromethyl-1H-pyrazole-5-carboxylic acid as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.59-1.73 (1H, m), 1.82-1.98 (3H, m),3.05-3.17 (1H, m), 3.29-3.39 (1H, m), 3.46-3.54 (1H, m), 3.59-3.69 (2H,m), 3.76 (3H, s), 3.85-3.94 (1H, m), 6.59-6.66 (1H, m), 6.73-6.80 (1H,m), 7.21-7.30 (1H, m), 7.32-7.38 (2H, m), 7.39-7.44 (2H, m), 7.46-7.49(1H, m), 7.51-7.54 (1H, m).

ESI-MS (m/e): 497.1 [M+H]⁺

Example 98 Synthesis of 3-Isobutyl—N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and3-isobutyl-1H-pyrazole-5-carboxylic acid as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.91 (6H, d, J=6.7 Hz), 1.51-1.63 (1H, m),1.65-1.83 (2H, m), 1.85-1.94 (1H, m), 2.05-2.13 (1H, m), 2.51 (2H, d,J=7.0 Hz), 2.93-3.03 (1H, m), 3.08-3.15 (1H, m), 3.33-3.40 (1H, m),3.51-3.58 (1H, m), 3.60-3.69 (1H, m), 3.75 (3H, s), 3.80-3.86 (1H, m).

ESI-MS (m/e): 485.2 [M+H]⁺

Example 99 Synthesis ofN-({1-[(1-Methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-3-phenyl-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and 3-phenyl-1H-pyrazole-5-carboxylicacid as the raw material.

1H-NMR (DMSO-d6)δ: 1.36-1.46 (1H, m), 1.60-1.76 (2H, m), 2.09-2.20 (1H,m), 2.67-2.83 (1H, m), 2.91-3.01 (1H, m), 3.43-3.51 (1H, m), 3.54-3.63(1H, m), 3.75 (3H, s), 3.79-3.85 (1H, m), 7.07 (1H, s), 7.20-7.56 (10H,m), 7.77-7.82 (1H, m), 7.83-7.86 (1H, m).

ESI-MS (m/e): 505.2 [M+H]⁺

Example 100 Synthesis of3-(2-Furyl)-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and3-(2-furyl)-1H-pyrazole-5-carboxylic acid as the raw material.

1H-NMR (CD3OD) δ: 1.50-1.64 (1H, m), 1.69-1.87 (2H, m), 2.09-2.21 (1H,m), 2.86-2.97 (1H, m), 3.01-3.10 (1H, m), 3.48-3.58 (1H, m), 3.70-3.76(1H, m), 3.79-3.88 (4H, m), 6.51-6.60 (1H, m), 6.72-6.80 (1H, m),6.84-6.92 (1H, m), 7.25-7.32 (1H, m), 7.37-7.45 (2H, m), 7.53-7.59 (2H,m), 7.62 (1H, s), 7.72-7.81 (2H, m).

ESI-MS (m/e): 495.2 [M+H]⁺

Example 101 Synthesis of3-tert-Butyl-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and3-tert-butyl-1H-pyrazole-5-carboxylic acid as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.30 (9H, s), 1.51-1.86 (3H, m), 2.02-2.12(1H, m), 2.98-3.08 (1H, m), 3.10-3.18 (1H, m), 3.31-3.40 (1H, m),3.49-3.57 (1H, m), 3.70-3.87 (5H, m), 6.48-6.52 (1H, m), 6.56-6.64 (1H,m), 7.21-7.28 (1H, m), 7.33-7.40 (2H, m), 7.42-7.45 (1H, m), 7.46-7.51(3H, m).

ESI-MS (m/e): 485.2 [M+H]⁺

Example 102 Synthesis ofN-({1-[(1-Methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-3-propyl-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 15 and 3-propyl-1H-pyrazole-5-carboxylicacid as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.95 (3H, t, J=7.3 Hz), 1.47-1.84 (5H, m),2.04-2.14 (1H, m), 2.62 (2H, t, J=7.3 Hz), 2.90-3.00 (1H, m), 3.06-3.16(1H, m), 3.31-3.42 (1H, m), 3.52-3.62 (2H, m), 3.76 (3H, s), 3.79-3.88(1H, m), 6.49 (1H, s), 6.71-6.82 (1H, m), 7.20-7.28 (1H, m), 7.33-7.39(2H, m), 7.41-7.53 (4H, m).

ESI-MS (m/e): 471.2 [M+H]⁺

Example 103 Synthesis of3-Ethyl-N-(5-isopropoxypyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-3-carboxamide

The title compound was synthesized as in Example 44, using the titlecompound of Production Example 16 and the title compound of ProductionExample 20 as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.89 (3H, t, J=7.6 Hz), 1.33 (6H, d, J=5.9Hz), 1.50-1.63 (1H, m), 1.68-1.88 (4H, m), 2.14-2.23 (1H, m), 2.84-2.90(1H, m), 2.94-3.03 (1H, m), 3.56-3.64 (1H, m), 3.77 (3H, s), 3.80-3.87(1H, m), 4.45-4.55 (1H, m), 7.20-7.25 (1H, m), 7.48-7.52 (2H, m),7.98-8.01 (1H, m), 8.11-8.15 (1H, m), 8.51 (1H, br s).

ESI-MS (m/e): 436.2 [M+H]⁺

Example 104 Synthesis of3-Ethyl-N-(5-isopropoxy-1H-pyrazol-3-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-3-carboxamide(1) Synthesis of3-Ethyl-N-(5-isopropoxy-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazol-3-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-3-carboxamide

The title compound was synthesized as in Example 44, using the titlecompound of Production Example 16 and the title compound of ProductionExample 21 as the raw material.

(2) Synthesis of Title Compound

The compound (83 mg, 0.15 mmol) synthesized in (1), TFA (0.9 mL), anddistilled water (0.1 mL) were stirred at room temperature for 2 hours.The reaction mixture was diluted with a saturated sodium hydrogencarbonate aqueous solution, and extracted with ethyl acetate. Theorganic layer was collected, and washed once with saturated brine. Theorganic layer was then dried over magnesium sulfate, and concentratedunder reduced pressure. The resulting residue was then purified usingsilica gel column chromatography to obtain the title compound (32 mg,50%).

1H-NMR (400 MHz, CDCl₃, δ): 0.86 (3H, t, J=7.6 Hz), 1.18-1.44 (8H, m),1.56-1.77 (2H, m), 1.81-1.92 (1H, m), 2.22-2.33 (1H, m), 2.61-2.77 (2H,m), 3.70-3.83 (4H, m), 3.99-4.08 (1H, m), 4.65-4.75 (1H, m), 5.51 (1H,s), 7.47-7.56 (2H, m), 9.14 (1H, br s).

ESI-MS (m/e): 425.2 [M+H]⁺

Example 105 Synthesis of(1R*,4S*,6R*)-N-(5-Isopropoxy-1H-pyrazol-3-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide

The title compound was synthesized as in Example 104, using the titlecompound of Production Example 6 and the title compound of ProductionExample 21 as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.34 (6H, d, J=6.3 Hz), 1.41-1.52 (1H, m),1.54-1.64 (1H, m), 1.70-1.89 (3H, m), 1.99-2.07 (1H, m), 2.18-2.27 (1H,m), 3.06-3.17 (2H, m), 3.41-3.49 (1H, m), 3.78 (3H, s), 4.22-4.27 (1H,m), 4.55-4.66 (1H, m), 5.69 (1H, br s), 7.44-7.50 (1H, m), 7.56-7.60(1H, m), 10.45 (1H, br s).

ESI-MS (m/e): 423.2 [M+H]⁺

Example 106 Synthesis of3-Isopropyl-N-{1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 17 and3-isopropyl-1H-pyrazole-5-carboxylic acid as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.27 (6H, d, J=7.3 Hz), 1.71-1.82 (1H, m),1.87-2.02 (2H, m), 2.67-2.81 (2H, m), 2.93-3.07 (2H, m), 3.73 (3H, s),3.84-3.96 (2H, m), 7.20-7.27 (2H, m), 7.29-7.35 (2H, m), 7.41-7.44 (1H,m), 7.46-7.53 (3H, m), 7.68-7.74 (1H, m).

ESI-MS (m/e): 457.2 [M+H]⁺

Example 107 Synthesis of3-Cyclopropyl-N-{1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}-1H-pyrazole-5-carboxamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 17 and3-cyclopropyl-1H-pyrazole-5-carboxylic acid as the raw material.

1H-NMR (400 MHz, CDCl₃, δ): 0.69-0.75 (2H, m), 0.92-0.99 (2H, m),1.69-1.79 (1H, m), 1.83-2.02 (3H, m), 2.67-2.82 (2H, m), 2.96-3.06 (1H,m), 3.73 (3H, s), 3.84-3.96 (2H, m), 6.37 (1H, s), 7.20-7.26 (1H, m),7.29-7.35 (2H, m), 7.42-7.51 (4H, m), 7.67 (1H, br s).

ESI-MS (m/e): 455.2 [M+H]⁺

Example 108 Synthesis of4-Isopropoxy-N-{1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}benzamide

The title compound was synthesized as in Example 93, using the titlecompound of Production Example 17 and 4-isopropoxybenzoic acid as theraw material.

1H-NMR (400 MHz, CDCl₃, δ): 1.36 (6H, d, J=5.4 Hz), 1.73-2.06 (3H, m),2.66-2.74 (1H, m), 2.76-2.84 (2H, m), 3.07-3.16 (1H, m), 3.71 (3H, s),3.85-4.00 (2H, m), 4.55-4.69 (1H, m), 6.89-6.95 (2H, m), 7.20-7.28 (1H,m), 7.30-7.50 (7H, m), 7.83-7.90 (2H, m).

ESI-MS (m/e): 483.2 [M+H]⁺

Production Example 1 Synthesis of (1R*,4S*,6R*)-2-(Butylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxylic Acid (1) Synthesis ofMethyl(1R*,4S*,6R*)-2-(butylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxylate

Triethylamine (0.51 mL, 3.7 mmol) and 1-butanesulfonyl chloride (0.233mL, 1.84 mmol) were added to a chloroform (5 mL) solution of methyl2-azabicyclo[2.2.2]octane-6-carboxylate hydroiodide (298 mg, 0.989 mmol)synthesized according to the method described in literature (Chem.Pharm. Bull. 53(1) 81-85 (2005)), and the mixture was stirred at roomtemperature for 13 hours. The reaction mixture was washed once withdistilled water, and once with a saturated sodium hydrogen carbonateaqueous solution. The organic layer was dried over magnesium sulfate,and concentrated under reduced pressure. The resulting residue was thenpurified using silica gel column chromatography to obtain the target(157 mg, 55%).

(2) Synthesis of Title Compound

A 5N-sodium hydroxide aqueous solution (1.5 mL) was added to a methanol(5 mL) solution of the compound (145 mg, 0.5 mmol) obtained in (1), andthe mixture was stirred at room temperature for 17 hours. The reactionmixture was ice-cooled, neutralized with 5N-hydrochloric acid aqueoussolution, and extracted with chloroform. The organic layer wascollected, dried over magnesium sulfate, and concentrated under reducedpressure to obtain the title compound (134 mg, 97%).

Production Example 2 Synthesis of(1R*,4S*,6R*)-N-(4-Isopropoxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamideHydrochloride (1) Synthesis of 2-tert-Butyl6-methyl(1R*,4S*,6R*)-2-azabicyclo[2.2.2]octane-2,6-dicarboxylate

Triethylamine (4.4 mL, 31.8 mmol), di-tert-butyl dicarbonate (3.47 g,15.9 mmol), and N,N-dimethyl-4-aminopyridine (97 mg, 0.79 mmol) wereadded to a chloroform (30 mL) solution of methyl2-azabicyclo[2.2.2]octane-6-carboxylate hydroiodide (2.36 g, 7.94 mmol)synthesized according to the method described in literature (Chem.Pharm. Bull. 53(1)81-85 (2005)), and the mixture was stirred at roomtemperature for 24 hours. After washing the reaction mixture twice witha saturated sodium hydrogen carbonate aqueous solution, the organiclayer was dried over magnesium sulfate, and concentrated under reducedpressure. The resulting residue was then purified using silica gelcolumn chromatography to obtain the target (2.05 g, 96%).

(2) Synthesis of(1R*,4S*,6R*)-2-(tert-Butoxycarbonyl)-2-azabicyclo[2.2.2]octane-6-carboxylicAcid

The target was obtained as in Production Example 1(2), using thecompound obtained in (1).

(3) Synthesis of tert-Butyl(1R*,4S*,6R*)-6-{[(4-isopropoxyphenyl)amino]carbonyl}-2-azabicyclo[2.2.2]octane-2-carboxylate

4-Isopropoxyaniline (1.49 g, 9.87 mmol), and1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(hereinafter, “WSC”; 1.89 g, 9.87 mmol) were added to a pyridine (20 mL)solution of the compound (1.68 g, 6.58 mmol) synthesized in (2), and themixture was stirred at room temperature for 14 hours. The reactionmixture was concentrated under reduced pressure, and, after addition ofethyl acetate, washed once with distilled water, once with 1N-hydrochloric acid aqueous solution, and once with 1N-sodium hydroxideaqueous solution. The organic layer was dried over magnesium sulfate,and concentrated under reduced pressure. The resulting residue was thenpurified using silica gel column chromatography to obtain the target(1.26 g, 49%).

(4) Synthesis of Title Compound

A 4 N-hydrochloric acid-ethyl acetate solution (8.1 mL) was added to achloroform (10 mL) solution of the compound (1.26 g, 3.24 mmol)synthesized in (3), and the mixture was stirred at room temperature for13 hours. The reaction mixture was then concentrated under reducedpressure to obtain the title compound (1.15 g, 100%).

Production Example 3 Synthesis of(1R*,2R*,5R*)-N-(4-Isopropoxyphenyl)-8-azabicyclo[3.2.1]octane-2-carboxamideHydrochloride (1) Synthesis of(1R*,2R*,5R*)-8-(tert-Butoxycarbonyl)-8-azabicyclo[3.2.1]octane-2-carboxylicAcid

The target was obtained as in Production Example 1(2), using8-tert-butyl2-methyl(1R*,2R*,5R*)-8-azabicyclo[3.2.1]octane-2,8-dicarboxylatesynthesized according to the method described in literature (TetrahedronLetteres, Vol. 38, No. 18, 3247-3248, 1997).

(2) Synthesis of tert-Butyl(1R*,2R*,5R*)-2-{[(4-isopropoxyphenyl)amino]carbonyl}-8-azabicyclo[3.2.1]octane-8-carboxylate

The title compound was synthesized as in Production Example 2(3), usingthe compound synthesized in (1) and 4-isopropoxyaniline.

(3) Synthesis of Title Compound

The title compound was obtained as in Production Example 2(4), using thecompound synthesized in (2).

Production Example 4 Synthesis of(1R*,4S*,6R*)-2-(Phenylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxylicAcid

The title compound was synthesized as in Production Example 1, usingmethyl 2-azabicyclo[2.2.2]octane-6-carboxylate hydroiodide andbenzenesulfonyl chloride as the raw material.

Production Example 5 Synthesis of(1R*,4S*,6R*)-2-(pyridin-2-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxylicAcid

The title compound was synthesized as in Production Example 1, usingmethyl 2-azabicyclo[2.2.2]octane-6-carboxylate hydroiodide andpyridine-2-sulfonyl chloride as the raw material.

Production Example 6 Synthesis of(1R*,4S*,6R*)-2-[(1-Methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxylicAcid

The title compound was synthesized as in Production Example 1, usingmethyl 2-azabicyclo[2.2.2]octane-6-carboxylate hydroiodide and1-methyl-1H-imidazole-4-sulfonyl chloride as the raw material.

Production Example 7 Synthesis of2-Methoxy-N-(piperidin-3-ylmethyl)benzamide Hydrochloride (1) Synthesisof tert-Butyl3-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]piperidine-1-carboxylate

Diisopropyl azodicarboxylate (1.17 mL, 6.04 mmol) was added to a THF (15mL) solution of tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate (1g, 4.64 mmol), phthalimide (888 mg, 6.04 mmol), and triphenylphosphine(1.58 g, 6.04 mmol), and the mixture was stirred at room temperature for24 hours. The reaction mixture was concentrated under reduced pressure,and the resulting residue was purified using silica gel columnchromatography to obtain the target (1.45 g, 90%).

(2) Synthesis of tert-Butyl 3-(aminomethyl)piperidine-1-carboxylate

Hydrazine monohydrate (1 mL, 20.58 mmol) was added to an ethanol (20 mL)solution of the compound (1.45 g, 4.21 mmol) synthesized in (1), and themixture was stirred at room temperature for 24 hours. The reactionsolution was filtered, and the filtrate was concentrated under reducedpressure. The residue was re-suspended in ethanol, and allowed to standunder ice-cooled conditions. After filtration, the filtrate wasconcentrated under reduced pressure to obtain the target (823 mg, 91%).

(3) Synthesis of Tert-Butyl 3-{[(2-methoxybenzoyl)amino]methyl}piperidine-1-carboxylate

HATU (293 mg, 0.77 mmol) was added to a DMF (3 mL) solution of thecompound (150 mg, 0.7 mmol) synthesized in (2), 2-methoxybenzoic acid(117 mg, 0.77 mmol), and diisopropylethylamine (0.27 mL, 1.54 mmol), andthe mixture was stirred at room temperature for 24 hours. After addingethyl acetate, the reaction mixture was washed twice with distilledwater, and once with saturated brine. The organic layer was dried overmagnesium sulfate, and concentrated under reduced pressure. Theresulting residue was then purified using silica gel columnchromatography to obtain the target (244 mg, 100%).

(4) Synthesis of Title Compound

The title compound was obtained as in Production Example 2(4), using thecompound obtained in (3).

Production Example 8 Synthesis of2-Methoxy-N-[(3-phenylpiperidin-3-yl)methyl]benzamide Hydrochloride (1)Synthesis of Tert-Butyl 3-(aminomethyl)-3-phenylpiperidine-1-carboxylate

The target was synthesized as in Production Example 7(1)(2), using theraw material tert-butyl3-(hydroxymethyl)-3-phenylpiperidine-1-carboxylate synthesized accordingthe method described in literature (WO9410165).

(2) Synthesis of Title Compound

The title compound was synthesized as in Production Example 7(3)(4),using the synthesized compound of (1) as the raw material.

Production Example 9 Synthesis of4-Isopropoxy-N-[(3-phenylpiperidin-3-yl)methyl]benzamide Hydrochloride

The title compound was synthesized as in Production Example 7, using theraw material tert-butyl3-(hydroxymethyl)-3-phenylpiperidine-1-carboxylate and4-isopropoxybenzoic acid synthesized according to the method describedin literature (WO9410165).

Production Example 10 Synthesis of5-Isopropoxy-N-[(3-phenylpiperidin-3-yl)methyl]pyridine-2-carboxamideHydrochloride

The title compound was synthesized as in Production Example 7, using theraw material tert-butyl3-(hydroxymethyl)-3-phenylpiperidine-1-carboxylate and5-isopropoxypyridine-2-carboxylic acid synthesized according to themethods described in literatures WO9410165 and JP2000344666A,respectively.

Production Example 11 Synthesis of4-Isopropoxy-N-[(3-methylpiperidin-3-yl)methyl]benzamide Hydrochloride(1) Synthesis of 1-tert-Butyl 3-ethyl3-methylpiperidine-1,3-dicarboxylate

A THF (5 mL) solution of 1-tert-butyl3-ethylpiperidine-1,3-dicarboxylate (1 g, 3.89 mmol) was added dropwiseto a THF (15 mL) solution of lithium diisopropylamide (5.83 mmol) in anitrogen atmosphere at −78 degrees over 5 minutes. The mixture wasraised to room temperature, and stirred for 50 minutes. The temperatureof the reaction mixture was lowered to −78 degrees again, and methyliodide (1.21 mL, 19.43 mmol) was added dropwise at −78 degrees over 5minutes. The reaction mixture was then raised to room temperature, andstirred for 5 hours. After being added to a saturated ammonium chlorideaqueous solution, the reaction mixture was stirred for a while, andextracted with diethyl ether. The organic layer was collected, washedonce with saturated brine, dried over magnesium sulfate, andconcentrated under reduced pressure. The resulting residue was thenpurified using silica gel column chromatography to obtain the target(698 mg, 66%).

(2) Synthesis of tert-Butyl3-(hydroxymethyl)-3-methylpiperidine-1-carboxylate

THF (5 mL) was added dropwise to lithium aluminum hydride (97 mg, 2.55mmol) in a nitrogen atmosphere at 0 degrees, and the mixture was stirredfor a while. Then, a THF (5 mL) solution of the compound (693 mg, 2.55mmol) obtained in (1) was added dropwise at 0 degrees. The reactionmixture was raised to room temperature, and further stirred for 2 hours.After adding sodium sulfate decahydrate, the reaction mixture wasstirred for 24 hours. After filtration, the filtrate was concentratedunder reduced pressure to obtain the target (418 mg, 71%).

(3) Synthesis of Title Compound

The title compound was synthesized as in Production Example 7, using thecompound synthesized in (2) and 4-isopropoxybenzoic acid.

Production Example 12 Synthesis ofN-[(3-Ethylpiperidin-3-yl)methyl]-4-isopropoxybenzamide Hydrochloride(1) Synthesis of 1-tert-Butyl 3-ethyl3-ethylpiperidine-1,3-dicarboxylate

The target was synthesized as in Production Example 11(1), using1-tert-butyl 3-ethylpiperidine-1,3-dicarboxylate and ethyl iodide as theraw material.

(2) Synthesis of Title Compound

The title compound was synthesis as in Production Example 11(2)(3),using the compound synthesized in (1).

Production Example 13 Synthesis of4-Isopropoxy-N-[(3-isopropylpiperidin-3-yl)methyl]benzamideHydrochloride

The title compound was synthesized as in Production Example 11, using1-tert-butyl 3-ethylpiperidine-1,3-dicarboxylate and 2-bromopropane asthe raw material.

Production Example 14 Synthesis ofN-[(3-Benzylpiperidin-3-yl)methyl]-4-isopropoxybenzamide Hydrochloride

The title compound was synthesized as in Production Example 11, using1-tert-butyl 3-ethylpiperidine-1,3-dicarboxylate and benzyl bromide asthe raw material.

Production Example 15 Synthesis of1-{1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methaneamine(1) Synthesis ofMethyl-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidine-3-carboxylate

The target was synthesized as in Production Example 1(1), using the rawmaterial methyl 3-phenylpiperidine-3-carboxylate described in literature(Tetrahedron Letters 42 (2001) 1645-1646) and1-methyl-1H-imidazole-4-sulfonyl chloride.

(2) Synthesis of{1-[(1-Methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methanol

The target was synthesized as in Production Example 11(2), using thecompound obtained in (1) as the raw material.

(3) Synthesis of Title Compound

The title compound was obtained as in Production Example 7(1)(2), usingthe compound synthesized in (2) as the raw material.

Production Example 16 Synthesis of3-Ethyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-3-carboxylicAcid (1) Synthesis of Ethyl 3-ethylpiperidine-3-carboxylateHydrochloride

The target was obtained as in Production Example 2(4), using thecompound synthesized in Production Example 12(1) as the raw material.

(2) Synthesis of Title Compound

The title compound was synthesized as in Production Example 1, using thecompound synthesized in (1) and 1-methyl-1H-imidazole-4-sulfonylchloride as the raw material.

Production Example 17 Synthesis of1-[(1-Methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidine-3-amineHydrochloride (1) Synthesis of1-[(1-Methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidine-3-carboxylicAcid

The target was obtained as in Production Example 1(2), using thecompound synthesized in Production Example 15(1) as the raw material.

(2) Synthesis of3-Isocyanate-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidine

Triethylamine (0.3 mL, 2.15 mmol) and DPPA (0.463 mL, 2.15 mmol) wereadded to a tert-butanol (5 mL) solution of the compound (500 mg, 1.43mmol) synthesized in (1), and the mixture was heated to reflux for 2hours. The solution was brought back to room temperature, andconcentrated under reduced pressure. The resulting residue was dissolvedin ethyl acetate, and washed once with 1N-sodium hydroxide aqueoussolution. The organic layer was dried over magnesium sulfate, andconcentrated under reduced pressure. The resulting residue was filteredafter washing with diethyl ether, and dried under reduced pressure toobtain the target (393 mg, 79%).

(3) Synthesis of Title Compound

The compound (383 mg, 11 mmol) synthesized in (2) was dissolved in a 4N-hydrochloric acid-1,4-dioxane solution (2.76 mL, 11.1 mmol), and themixture was stirred at 80 degrees for 24 hours. The solution was broughtback to room temperature, and concentrated under reduced pressure toobtain the title compound (401 mg, 100%).

Production Example 18 Synthesis ofN-(2-Methoxyphenyl)-N′-[(3-phenylpiperidin-3-yl)methyl]ureaHydrochloride (1) Synthesis of Tert-Butyl3-[({[(2-methoxyphenyl)amino]carbonyl}amino)methyl]-3-phenylpiperidine-1-carboxylate

Triethylamine (0.036 mL, 0.258 mmol) and 2-methoxyphenyl isocyanate(28.2 mg, 0.189 mmol) were added to a chloroform (1 mL) solution of thecompound (50 mg, 0.172 mmol) synthesized in Production Example 8(1), andthe mixture was stirred at room temperature for 24 hours. The reactionmixture was washed once with distilled water, and once with a saturatedsodium hydrogen carbonate aqueous solution. The organic layer was driedover magnesium sulfate, and concentrated under reduced pressure. Theresulting residue was then purified using silica gel columnchromatography to obtain the target (76 mg, 100%).

(2) Synthesis of Title Compound

The title compound was obtained as in Production Example 2(4), using thecompound synthesized in (1) as the raw material.

Production Example 19 Synthesis of(1R*,4S*,6R*)-N-(3-Methoxypyridin-2-yl)-2-azabicyclo[2.2.2]octane-6-carboxamideHydrochloride

The title compound was synthesized as in Production Example 2, usingmethyl 2-azabicyclo[2.2.2]octane-6-carboxylate hydroiodide and2-amino-3-methoxypyridine as the raw material.

Production Example 20 Synthesis of 5-Isopropoxypyridine-2-amineHydrochloride (1) Synthesis of 2-Bromo-5-isopropoxypyridine

2-Bromopropane (1.13 mL, 12 mmol) and potassium carbonate (1.43 g, 10.4mmol) were successively added to a DMF (10 mL) solution of6-bromopyridin-3-ol (1 g, 5.75 mmol), and the mixture was stirred at 80degrees for 2 hours. The solution was brought back to room temperature,diluted with ethyl acetate, and washed twice with distilled water, andonce with saturated brine. The organic layer was dried over magnesiumsulfate, and concentrated under reduced pressure to obtain the target(1.28 g, 100%).

(2) Synthesis of Ethyl 5-isopropoxypyridine-2-carboxylic Acid

Palladium acetate (31.2 mg, 0.14 mmol) and1,1′-bis(diphenylphosphino)ferrocene (77.1 mg, 0.14 mmol) were added toa mixture of ethanol (6 mL) and DMF (3 mL) containing the compound (600mg, 2.78 mmol) obtained in (1), and stirred at 50 degrees for 22 hoursin the presence of carbon monoxide. The reaction mixture was thendiluted with ethyl acetate, and washed twice with a saturated sodiumhydrogen carbonate aqueous solution, and once with saturated brine. Theresulting organic layer was dried over magnesium sulfate, andconcentrated under reduced pressure. The resulting residue was thenpurified using silica gel column chromatography to obtain the target(386 mg, 66%).

(3) Synthesis of 5-Isopropoxypyridine-2-carboxylic Acid

A 5N-sodium hydroxide aqueous solution (1.8 mL) was added to an ethanol(3 mL) solution of the compound (386 mg, 1.84 mmol) obtained in (2), andthe mixture was stirred at 50 degrees for 3 hours. The reaction mixturewas ice-cooled, neutralized with 5N-hydrochloric acid aqueous solution,and extracted with chloroform. The organic layer was collected, driedover magnesium sulfate, and concentrated under reduced pressure toobtain the target (258 mg, 78%).

(4) Synthesis of Tert-Butyl (5-isopropoxypyridin-2-yl)carbamate

Triethylamine (0.585 mL, 4.2 mmol) and diphenylphosphoryl azide (0.453mL, 2.1 mmol) were successively added to a tert-butanol (5 mL) solutionof the compound (255 mg, 1.4 mmol) obtained in (3), and the mixture wasstirred at 100 degrees for 5 hours. The reaction mixture was broughtback to room temperature, and concentrated under reduced pressure. Theresidue was dissolved in ethyl acetate, and washed twice with 1N-sodiumhydroxide aqueous solution, and once with saturated brine. The organiclayer was dried over magnesium sulfate, and concentrated under reducedpressure. The resulting residue was then purified using silica gelcolumn chromatography to obtain the target (137 mg, 39%).

(5) Synthesis of Title Compound

A 4N-hydrochloric acid-ethyl acetate solution (4.5 mL) was added to achloroform (5 mL) solution of the compound (137 mg, 0.54 mmol) obtainedin (4), and the mixture was stirred at room temperature for 18 hours.The reaction mixture was then concentrated under reduced pressure toobtain the title compound (102 mg, 100%).

Production Example 21 Synthesis of5-Isopropoxy-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrazole-3-amine

Sodium hydride (60%, 425 mg, 10.63 mmol) was added to a DMF (mL)solution of 5-isopropoxy-1H-pyrazole-3-amine (1.5 g, 10.63 mmol) at −18degrees, and the mixture was stirred for 30 minutes. Then,2-(trimethylsilyl)ethoxymethyl chloride (1.89 mL, 10.63 mmol) was addeddropwise, and stirred at room temperature for 24 hours. The reactionmixture was then diluted with ethyl acetate, and washed once withdistilled water, and once with saturated brine. The organic layer wasdried over magnesium sulfate, and concentrated under reduced pressure.The resulting residue was then purified using silica gel columnchromatography to obtain the title compound (462 mg, 16%).

INDUSTRIAL APPLICABILITY

A compound according to the present invention has an excellent LCEinhibiting effect, and is therefore useful as a remedy for a variety ofdiseases involving LCE, for example, such as cardiovascular disease,neurologic disease, metabolic disease, reproductive disease, anddigestive disease. A compound according to the present invention is alsouseful as a herbicide.

1-17. (canceled)
 18. A compound represented by the following Formula (I)or a pharmaceutically acceptable salt thereof;

wherein, Z is selected from the group consisting of the followingFormulae (II-1), (II-2), and (II-3)

where n1, n2, and n3 are 0, 1, or 2, respectively wherein, R¹ representsC₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or heteroaryl, wherein the alkyl,cycloalkyl, aryl, or heteroaryl are unsubstituted or substituted with asubstituent selected from the group consisting of: hydroxy, cyano,carboxyl, sulfo, halogen, C₁₋₆ alkyl, halo C₁₋₆ alkyl, C₃₋₈ cycloalkyl,C₁₋₆ alkoxy, halo C₁₋₆ alkoxy, amino, wherein the amino is unsubstitutedor substituted with 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls,carbamoyl, wherein the carbamoyl is unsubstituted or substituted with 1to 2 C₁₋₆ alkyls, aryls, or heteroaryls, sulfanyl, wherein the sulfanylis unsubstituted or substituted with one C₁₋₆ alkyl, aryl, orheteroaryl, C₁₋₆ alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, C₁₋₆alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, sulfamoyl, wherein thesulfamoyl is unsubstituted or substituted with 1 to 2 C₁₋₆ alkyls,aryls, or heteroaryls, C₁₋₆ alkylsulfonylamino, arylsulfonylamino,heteroarylsulfonylamino, C₁₋₆ alkylcarbonyl, arylcarbonyl,heteroarylcarbonyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl,heteroaryloxycarbonyl, carbamoylamino, wherein the carbamoylamino isunsubstituted or substituted with 1 to 2 C₁₋₆ alkyls, aryls, orheteroaryls, C₁₋₆ alkoxycarbonylamino, aryloxycarbonylamino,heteroaryloxycarbonylamino, C₁₋₆ alkylcarbonylamino, arylcarbonylamino,heteroarylcarbonylamino, aryl, heteroaryl, aralkyl, heteroaralkyl,aralkyloxy, and heteroaralkyloxy; R² represents phenyl or heteroaryl,wherein the phenyl or heteroaryl may be substituted with a substituentselected from the group consisting of: hydroxy, cyano, carboxyl, sulfo,halogen, C₁₋₆ alkyl, halo C₁₋₆ alkyl, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, haloC₁₋₆ alkoxy, amino, wherein the amino is unsubstituted or substitutedwith 1 to 2 C₁₋₆ alkyls, aryls, or heteroaryls, carbamoyl, wherein thecarbamoyl is unsubstituted or substituted with 1 to 2 C₁₋₆ alkyls,aryls, or heteroaryls, sulfanyl, wherein the sulfanyl is unsubstitutedor substituted with one C₁₋₆ alkyl, aryl, or heteroaryl, C₁₋₆alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, C₁₋₆ alkylsulfonyl,arylsulfonyl, heteroarylsulfonyl, sulfamoyl, wherein the sulfamoyl isunsubstituted or substituted with 1 to 2 C₁₋₆ alkyls, aryls, orheteroaryls, C₁₋₆ alkylsulfonylamino, arylsulfonylamino,heteroarylsulfonylamino, C₁₋₆ alkylcarbonyl, arylcarbonyl,heteroarylcarbonyl, C₁₋₆ alkoxycarbonyl, aryloxycarbonyl,heteroaryloxycarbonyl, carbamoylamino, wherein the carbamoylamino isunsubstituted or substituted with 1 to 2 C₁₋₆ alkyls, aryls, orheteroaryls, C₁₋₆ alkoxycarbonylamino, aryloxycarbonylamino,heteroaryloxycarbonylamino, C₁₋₆ alkylcarbonylamino, arylcarbonylamino,heteroarylcarbonylamino, aryl, wherein the aryl is unsubstituted orsubstituted with C₁₋₆ alkoxy, heteroaryl, aryloxy, heteroaryloxy,aralkyl, heteroaralkyl, aralkyloxy, and heteroaralkyloxy; R³ representsa hydrogen atom, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aralkyl, heteroaralkyl,aryl, or heteroaryl, wherein the alkyl, cycloalkyl, aralkyl,heteroaralkyl, aryl, or heteroaryl is unsubstituted or substituted witha substituent selected from the group consisting of halogen, C₁₋₆ alkyl,halo C₁₋₆ alkyl, C₁₋₆ alkoxy, and halo C₁₋₆ alkoxy; and M₁, M₂, M₃, andM₄ represent each independently a hydrogen atom or C₁₋₆ alkyl which maybe substituted with halogen; or M₁, together with M₂, M₃ or M₄, forms—CH₂— or —CH₂—CH₂—, or M₄, together with M₂, forms —CH₂— or —CH₂—CH₂—,provided that any two of M₁, M₂, M₃, and M₄ together form —CH₂— or—CH₂—CH₂— when R³ is a hydrogen atom.
 19. The compound or thepharmaceutically acceptable salt thereof according to claim 1, whereinR¹ is C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or heteroaryl, and wherein theC₁₋₆ alkyl, the C₃₋₈ cycloalkyl, the aryl, and the heteroaryl are eachunsubstituted or substituted with a substituent selected from the groupconsisting of halogen, C₁₋₆ alkyl, and C₁₋₆ alkoxy.
 20. The compound orthe pharmaceutically acceptable salt thereof according to claim 1,wherein R¹ is one of propyl, isopropyl, butyl, isobutyl, cyclopropyl,phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl,3-fluorophenyl, 4-fluorophenyl, 2-trifluoromethylphenyl,3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-methoxyphenyl,3-methoxyphenyl, 4-methoxyphenyl, pyridin-2-yl, pyridin-3-yl,pyridin-4-yl, pyrimidin-2-yl, pyrazin-2-yl, pyridazin-3-yl, 2-thienyl,3-thienyl, 1-methyl-1H-imidazol-4-yl, 5-methyl-1,3,4-thiadiazol-2-yl,1,3-thiazol-2-yl, 1,3-oxazol-2-yl, and 1,3,4-thiadiazol-2-yl.
 21. Thecompound or the pharmaceutically acceptable salt thereof according toclaim 1, wherein R² is phenyl or heteroaryl, and wherein the phenyl andthe heteroaryl are each unsubstituted or substituted with a substituentselected from the group consisting of halogen, C₁₋₆ alkyl, halo C₁₋₆alkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, aryl, aralkyl, and aralkyloxy. 22.The compound or the pharmaceutically acceptable salt thereof accordingto claim 1, wherein R² is one of phenyl, 2-fluorophenyl, 3-fluorophenyl,4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-methylphenyl,3-methylphenyl, 4-methylphenyl, 2-isopropylphenyl, 3-isopropylphenyl,4-isopropylphenyl, 2-isopropoxyphenyl, 3-isopropoxyphenyl,4-isopropoxyphenyl, 2-benzylphenyl, 3-benzylphenyl, 4-benzylphenyl,2-benzyloxyphenyl, 3-benzyloxyphenyl, 4-benzyloxyphenyl,5-isopropoxyphenylpyridin-2-yl, 6-isopropoxyphenylpyridin-3-yl,5-isopropoxypyrimidin-2-yl, 3-methoxypyridin-2-yl,3-cyclopropyl-1H-pyrazol-5-yl, and 5-isopropoxy-1H-pyrazol-3-yl.
 23. Thecompound or the pharmaceutically acceptable salt thereof according toclaim 1, wherein Z is of the Formula (II-1), and wherein n1 is
 0. 24. Acompound or a pharmaceutically acceptable salt thereof according toclaim 1, wherein Z is of the Formula (II-2), and wherein n2 is
 1. 25.The compound or the pharmaceutically acceptable salt thereof accordingto claim 1, wherein R³ is a hydrogen atom.
 26. The compound or thepharmaceutically acceptable salt thereof according to claim 1, whereinM₁, together with M₃, forms —CH₂— or —CH₂—CH₂—, and M₂ and M₄independently represent a hydrogen atom, or C₁₋₆ alkyl unsubstituted orsubstituted with halogen.
 27. The compound or the pharmaceuticallyacceptable salt thereof according to claim 9, wherein M₁, together withM₃, forms —CH₂—CH₂—, and M₂ and M₄ each represent a hydrogen atom. 28.The compound or the pharmaceutically acceptable salt thereof accordingto claim 1, wherein M₁, together with M₂, forms —CH₂— or —CH₂—CH₂—, andM₃ and M₄ independently represent a hydrogen atom, or C₁₋₆ alkyloptionally substituted with halogen.
 29. The compound or thepharmaceutically acceptable salt thereof according to claim 11, whereinM₁, together with M₂, forms —CH₂—CH₂—, and M₃ and M₄ each represent ahydrogen atom.
 30. The compound or the pharmaceutically acceptable saltthereof according to claim 1, wherein M₁, M₂, M₃, and M₄ are allhydrogen atoms.
 31. A compound or the pharmaceutically acceptable saltthereof selected from the group consisting of:(1R**,4S**,6R**)-N-(4-isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide;(1S**,4R**6S**)-N-(4-isopropoxyphenyl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide;(1R*,4S*,6R*)-2-(butylsulfonyl)-N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-azabicyclo[2.2.2]octane-6-carboxamide;(1R*,4S*,6R*)-N-(5-isopropoxypyridin-2-yl)-2-(pyridin-2-ylsulfonyl)-2-azabicyclo[2.2.2]octane-6-carboxamide;(1R**,4S**,6R**)-N-(5-isopropoxypyridin-2-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide;(1S**,4R**,6S**)-N-(5-isopropoxypyridin-2-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide;2-methoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide;4-isopropoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide;4-isopropoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)benzamide;5-isopropoxy-N-{[3-phenyl-1-(propylsulfonyl)piperidin-3-yl]methyl}pyridine-2-carboxamide;5-isopropoxy-N-{[3-phenyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}pyridine-2-carboxamide;5-isopropoxy-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)pyridine-2-carboxamide;4-isopropoxy-N-{[3-methyl-1-(phenylsulfonyl)piperidin-3-yl]methyl}benzamide;4-isopropoxy-N-{[3-methyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}benzamide;N-{[3-ethyl-1-(pyridin-2-ylsulfonyl)piperidin-3-yl]methyl}-4-isopropoxybenzamide;N-({3-ethyl-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidin-3-yl}methyl)-4-isopropoxybenzamide;3-isobutyl-N-({1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-3-phenylpiperidin-3-yl}methyl)-1H-pyrazole-5-carboxamide;3-ethyl-N-(5-isopropoxypyridin-2-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-3-carboxamide;3-ethyl-N-(5-isopropoxy-1H-pyrazol-3-yl)-1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]piperidine-3-carboxamide;and(1R*,4S*,6R*)-N-(5-isopropoxy-1H-pyrazol-3-yl)-2-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-2-azabicyclo[2.2.2]octane-6-carboxamide.32. A long chain fatty acyl elongase (LCE) inhibitor, which comprisesthe compound or the pharmaceutically acceptable salt thereof of claim 1as an active ingredient.
 33. A pharmaceutical composition, whichcomprises the compound or the pharmaceutically acceptable salt thereofof any one of claim
 1. 34. A method for treating diabetes mellitus,obesity, or non-alcoholic fatty liver, comprising administering to asubject a compound or the pharmaceutically acceptable salt thereof ofclaim 1.